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Combination antiretroviral therapy, despite being potent and life-prolonging, is not curative and does not eradicate
HIV-1 infection since interruption of treatment inevitably results in a rapid rebound of viremia. Reactivation of
latently infected cells harboring transcriptionally silent but replication-competent proviruses is a potential source of
persistent residual viremia in cART-treated patients. Although multiple reservoirs may exist, the persistence of
resting CD4+ T cells carrying a latent infection represents a major barrier to eradication. In this review, we will
discuss the latest reports on the molecular mechanisms that may regulate HIV-1 latency at the transcriptional level,
including transcriptional interference, the role of cellular factors, chromatin organization and epigenetic
modifications, the viral Tat trans-activator and its cellular cofactors. Since latency mechanisms may also operate at
the post-transcriptional level, we will consider inhibition of nuclear RNA export and inhibition of translation by
microRNAs as potential barriers to HIV-1 gene expression. Finally, we will review the therapeutic approaches and
clinical studies aimed at achieving either a sterilizing cure or a functional cure of HIV-1 infection, with a special
emphasis on the most recent pharmacological strategies to reactivate the latent viruses and decrease the pool of
viral reservoirs.
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Human Immunodeficiency Virus type 1 (HIV-1) is the
cause of the acquired immunodeficiency syndrome (AIDS)
and the responsible of a devastating pandemic that affects
around 34 million people worldwide (UNAIDS, 2011).
Thirty years after the discovery of HIV-1, the virus can
still not be cured. Combination antiretroviral therapy
(cART) has significantly reduced AIDS-related morbidity
and mortality. New regimens are more potent, have fewer
side effects and a low pill burden. However, these anti-
retroviral drugs do not fully restore health or a normal im-
mune status in HIV-1 infected individuals. Patients
experience co-morbidities, such as increased cardiovascular
disease, bone disorders and cognitive impairment. Interrup-
tion of cART almost invariably leads to the re-emergence of
detectable viral replication and the progression of AIDS.
Moreover, a significant proportion of patients fail to main-
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reproduction in any medium, provided the orand/or because of the development of drug resistance
(reviewed in [1]). Even with optimal treatment and adher-
ence, some patients have problems to keep the virus under
control and/or show progressive immune pathology
manifesting increased mortality compared to HIV-1 unin-
fected individuals. This increased mortality is closely associ-
ated with inflammation, which persists in cART-treated
HIV-infected individuals despite levels of plasma viremia
below detection limits. Chronic, pathological immune acti-
vation is a key factor in progression to AIDS in untreated
HIV-infected individuals. Today, only a small percentage of
the HIV-infected people who need treatment worldwide
have access to cART. Clearly, more innovative approaches
are urgently needed to address these issues.
Untreated HIV-1 infection is characterized by continu-
ous viral replication that drives CD4+ T cell loss and pre-
dicts disease progression. During cART, the plasma virus
levels fall below the level of detection of current classical
assays (50 copies of viral/HIV-1 RNA per ml of plasma).
This decrease goes through several phases of decay corre-
sponding to the half-lives of different populations of HIV-
infected cells, which are progressively eliminated (Figure 1).
The first decay phase is rapid, being related to the virusl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and




























Figure 1 Dynamics of plasma virus levels in a cART-treated HIV + individuals. After initiation of cART, viremia undergoes three phases
reflecting the decay rates of different populations of HIV-1 latently infected cells. The first phase represents the rapid decay of productively infected
CD4+ T cells (activated CD4+ T cells having a half-life of ~1 day). The cells responsible for the second phase, which have a half-life of about 14 days,
are not definitively identified (possibly partially activated CD4+ T cells or other cell types such as macropages or dendritic cells). The third phase is a
constant phase in which viremia reaches levels below the limit of detection of clinical assays (50 copies viral RNA per ml of plasma). During this
plateau phase, occasional viremic episodes (called blips) are detected despite cART. Reservoirs of HIV-1 are responsible for the low but stable level of
residual viremia observed during the third phase. This residual viremia is partly derived from the activation of latently infected resting (memory) CD4+
T cells (or subsets of these cells) and partly from another unknown cell source (such as long-lived HIV-infected cells). A rapid rebound of viremia is
observed if cART therapy is stopped. Therapeutic strategies achieving control of viremia below detection level after cART cessation could lead to a
functional cure. Strategies achieving elimination of HIV-1 from the human body could lead to a sterilizing cure.
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life of less than a day in the productively infected state [2].
The second phase reflects virus production by another
population of infected cells with a half-life of 1–4 weeks.
The third phase is a constant phase with no appreciable
decline, caused at least partially by the activation of resting
memory CD4+ T cells that start to produce virions. During
this constant phase, occasional viremic episodes (called
blips) are detected despite prolonged cART treatment from
latently infected T cells that became productive after a
transient activation of the immune system (i.e. caused by a
viral or bacterial infection). Moreover, during this constant
phase, a persistent residual low-level viremia (ranging from
1 to 5 copies of viral RNA/ml) can be detected in most pa-
tients using ultrasensitive RT-PCR assays. Persistent
viremia in cART-treated infected individuals could arise
from latently infected cellular reservoirs and/or residual
ongoing viral replication.
Two general forms of viral latency (reversibly non pro-
ductive state of infection) have been observed and can be
segregated based on whether or not the virus has inte-
grated into the host cell genome: pre-integration and post-
integration latency (reviewed in [3-5]). Pre-integration
latency results from partial or complete block of the viral
life cycle at steps prior to the integration of the virus into
the host genome (incomplete reverse transcription, im-
paired import of the pre-integration complex into the nu-
cleus or incomplete integration) [6,7]. Unintegrated formspersist in the cytoplasm of CD4+ T cells for only one day
and cannot account for the formation of long-term latently
infected reservoirs (reviewed in [8]). Although macro-
phages and some tissues like the brain may retain these
forms for a longer period, pre-integration latency appears
to be less clinically relevant [9,10]. Indeed, episomal HIV-1
cDNAs are used as surrogate markers for recently infected
cells in vivo [11,12]. Post-integration latency is a rare event
that occurs when a provirus fails to effectively express its
genome and is reversibly silenced after integration into the
host cell genome. This latent state is exceptionally stable
and is limited only by the lifespan of the infected cell and
its progeny. Post-integration latency is a multifactorial
phenomenon. Mechanisms that maintain HIV-1 latency
in vivo are incompletely understood. Latently infected cells
may be maintained by mechanisms operating at the post-
transcriptional level (i.e. inhibition of nuclear RNA export
and inhibition of HIV-1 translation by microRNAs). How-
ever, in the majority of latently infected cells, HIV-1 infec-
tion appears to be blocked at the transcriptional level.
HIV-1 transcriptional repression is crucial to the establish-
ment and maintenance of post-integration latency. Several
elements contribute to the transcriptional silencing of in-
tegrated HIV-1 proviruses (reviewed in [3,13,14]: 1) the
site of integration into the host cell genome, the cellular
chromatin environment at this site and mechanisms of
transcriptional interference; 2) the spatial sub-nuclear
positioning of the integrated provirus (reviewed in: [15]);
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such as NF-kappaB (Nuclear Factor Kappa-light-chain-en-
hancer of activated B cells) or NFAT (Nuclear Factor of Ac-
tivated T-cells), that are excluded from the nuclei of resting
cells and transiently activated by various stimuli; 4) the pres-
ence of transcriptional repressors, such as CTIP2 (COUP-
TF Interacting Protein 2), DSIF (DRB-Sensitivity Inducing
Factor), NELF (Negative Elongation Factor) and the family
of TRIM proteins (tripartite motif); 5) the chromatin struc-
ture of the HIV-1 promoter and the presence of a repressive
nucleosme (nuc-1); 6) the epigenetic control of the HIV-1
promoter (histone posttranslational modifications, such as
acetylation and methylation, and DNA methylation); 7) The
sequestration of the cellular positive transcription elongation
factor b (P-TEFb), composed of cyclin-dependent kinase 9
(cdk9) and human cyclin T1, in an inactive form by the
HEXIM-1 (hexamethylene bisacetamide (HMBA)-induced
protein 1)/7SK snRNA (7SK small nuclear RNA) regulatory
complex; 8) the sub-optimal concentration of the viral
transactivator Tat, which promotes transcription byFigure 2 Reactivation of HIV-1 transcriptional latency. During latency,
and only short mRNAs corresponding to TAR are produced. Nuc-1 is maint
transcription factor (YY1, CTIP-2, p50-p50 homodimer, CBF-1). The corepres
the HIV-1 5’ LTR and recruits HDACs and the HMT Suv39h1, which trimethy
methylation repressive marks such as H3K9Me2 or H3K27Me3 catalyzed by
latency. In addition, during latency, the HIV-1 promoter is hypermethylated
dotted arrows indicate that DNMTs are most likely recruited to the HIV-1 p
latent conditions, the active form of NF-kappaB (p50-p65 heterodimers) is s
(IκB), while NF-kappaB p50-p50 homodimers occupies the kappaB sites at t
and by STAT5Δ/p50 heterodimer in monocytic cells. The phosphorylated fo
resting CD4+ T cells, P-TEFb, composed of CDK9 and human cyclin T1, is se
complex. In this context, several compounds have been proposed for trasn
the hypoacetylated state of nuc-1, HMTIs (chaetocin, BIX-01294, DZNEP) to
PKC or Akt agonists (sprostratin, bryostatin) to activate the NF-kappaB signa
inducers of P-TEFb release (HMBA, JQ1).mediating the recruitment to the HIV-1 promoter of the
kinase complex P-TEFb, of histone-modifying enzymes and
of ATP-dependent chromatin-remodeling complexes re-
quired for nucleosomal disruption and transcriptional
processivity.
Several therapeutic approaches aimed at achieving ei-
ther a sterilizing cure (in which all replication-competent
virus is eradicated, Figure 1) or a functional cure (lack of
detectable viremia in the absence of cART despite the
presence of replication-competent HIV-1 for prolonged
periods together with normal or near normal immuno-
logical functions, Figure 1) are under scrutiny (Figure 2
and Table 1). In this context, further understanding of the
molecular mechanisms regulating HIV-1 latency (Figure 2)
and reactivation from latency in different target cells har-
boring the virus will help to devise novel strategies to
eliminate latent HIV-1 infection or to restrict the latent
pool to a size bearable by the host immune system. This
could allow individuals to envisage therapeutic interrup-
tions (“treatment-free windows”) and could lead tonuc-1 blocks transcriptional initiation and/or elongation, Tat is absent
ained hypoacethylated by HDACs recruited to the 5’LTR via several
sor CTIP-2 interacts with the Sp1 transcription factor at three sites in
lates H3K9 leading to the recruitment of HP1. Other histone
the HMT G9a and EZH2, respectively, are also implicated in HIV-1
at two CpG islands surrounding the HIV-1 transcriptional start site. The
romoter but this recruitment has not been demonstrated so far. In
equestered in the cytoplasm by the inhibitor of nuclear factor kappaB
he viral LTR region. The kappaB sites can also be occupied by CBF-1
rm of NFAT is also in the cytoplasm in latency conditions. Moreover, in
questered in an inactive form by the HEXIM-1/7SK snRNA regulatory
criptionalreactiation of HIV-1 including HDACIs (SAHA, VPA) to target
target HMTs, DNMTIs (5-Aza-CdR) to target 5’LTR DNA methylation,
ling pathway, cytokines (IL-2, IL-7, GM-CSF) to activate STAT5 and
Table 1 HIV cure clinical trials
Trial/investigator Intervention ClinicalTrials.gov Status
Optiprim ANRS 147 (A. Chèret) 3 vs 5 ARV at AHI NCT01033760 Ongoing
IntensVIH (A. Lafeuillade) RAL + MRV intensification NCT00935480 Ongoing
Eramune 01 (C. Katlama) IL7 + intensification RAL/MVC NCT01019551 Ongoing
Eramune 02 (R. Murphy) Vacc + intensification RAL/MVC NCT09976404 Ongoing
S. Deeks Disulfiram NCT01286259 Ongoing
D. Margolis Vorinostat (SAHA) NCT01319383 [229], Ongoing
S. Lewin Vorinostat (SAHA) NCT01365065 Ongoing
L. Østergaard Panobinostat NCT01680094 Ongoing
J. Lalezari ZFN (CCR5) NCT01252641 Ongoing
P. Tebas ZFN (CCR5) NCT00842634 Ongoing
A. Krishnan Autologous SC with anti-HIV genes NCT00569985 Ongoing
F. Maldarelli INFα 2b NCT01295515 Ongoing
Gilead Romidepsin NA To be started
S. Moreno Bryostatin NA To be started
H. Hatano Anti-PDI antibody NA To be started
A. Woolfrey Intervention autologous HIV resistant cells NA To be started
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ment of quality of life.
In this review, we will focus on the latest developments
leaving the previous enormous amount of work and dis-
coveries to further reading, including our previous reviews
on the same topic [3,5]. We will start discussing the po-
tential sources of residual viremia in cART-treated pa-
tients and the nature of the HIV-1 reservoirs and continue
with the establishment of in vitro models for latency and
the study of latency in the patient cells and in animal
models. Next, we will describe the recent progress in the
molecular understanding of HIV-1 persistence with a spe-
cial attention to strategies that are being proposed to tar-
get these pathways. Finally, we will discuss the therapeutic
options that are currently being proposed.
Potential sources of residual viremia in cART-
treated individuals
The low-level residual viremia in cART-treated patients is
indicative of active virus production, which can occur
without new rounds of infection and propagation of the
infection to additional cells. In principle, residual viremia
could result from a low degree of ongoing cycles of viral
replication (either in the presence of antiretroviral drugs
or in anatomical sanctuaries where drug penetration is
suboptimal), and/or reactivation of viral expression from
latently infected resting CD4+ T cells (harboring stably in-
tegrated, transcriptionally silent but replication-competent
proviruses), and/or the release of virus from other stable
reservoirs.
Concerning ongoing viral replication, it has been demon-
strated that productively infected CD4+ T cells persist inthe blood and gut-associated lymphoid tissue (GALT) of
infected individuals receiving cART. The precise mechan-
ism of this persistence has not been fully delineated but
homeostatic proliferation of latently infected resting CD4+
T cells [12] and a sub-optimal intracellular penetration of
antiretroviral drugs in lymphoid tissues may contribute to
this phenomenon. If viral replication continues during sup-
pressive therapy, low-level viremia would be reduced by the
addition of another antiretroviral compound. In this regard,
two studies have shown that intensification of conventional
cART leads to reduction of the level of cell-associated HIV-
1 RNA in CD4+ T cells in the terminal ileum [16] and to
the accumulation of circularized 2-LTRs DNA circles in
CD4+ T cells in the peripheral blood of some (30%)
infected individuals receiving cART [17]. Moreover, the
group of David Baltimore has reported that cell-to-cell
spread of HIV-1 permits ongoing replication despite cART
[18]. However, other intensification studies using
Raltegravir have not shown any noticeable diminution of
plasma viremia in infected individuals who had been on
cART and had maintained <50 copies/ml of HIV-1 RNA
([19-21], abstract 51, session 11 presented at the CROI,
2011). Moreover, most viral evolution studies failed to de-
tect evolutionary genetic changes in the persistent virus
population in the majority of cART patients [22-25].
In addition to ongoing viral replication, the cellular latent
reservoirs harboring transcriptionally silent but replication-
competent stably integrated HIV-1 proviruses are insensi-
tive to cART and able to escape from the host immune re-
sponse. They are therefore a permanent source for virus
reactivation and could be responsible for the rebound of
plasma viral load observed after cART interruption.
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might arise from several different sources including: 1)
long-lived HIV-1 infected cells that produce virus; 2) on-
going replication cycles in cells located in sanctuary sites
where drug levels are suboptimal such as a tissue-based
foci of viral replication within CD4+ T cells and/or mye-
loid cells; and/or 3) proliferation of latently infected cells
with regeneration of a stable reservoir of slowly dividing
infected cells.
Nature of cellular reservoirs
A viral reservoir can be defined as a cell type or anatom-
ical site where a replication competent form of the virus
persists for a longer time than in the main pool of actively
replicating virus. Over the years, researchers have found
that latency can exist in a range of anatomical sites and
cell types. The nature of the HIV-1 reservoirs has been re-
cently reviewed [26,27] and will be only briefly summa-
rized here. The most prominent ones are the CD4+ T-cell
subsets, primarily resting central memory T cells (TCM)
(defined as CD45RA- CCR7+ CD27+) and translational
memory T cells (TTM) (defined as CD45RA- CCR7-
CD27+) [12,28,29]. A critical issue is where these cells are
derived from in the infected patient. Direct infection of
quiescent T cells can occur ex vivo when cells are treated
with a selected set of chemokines [30-33] or by
spinoculation [34,35] (see chapter 5). Normally, however,
because of the presence of various blocks to the viral
lifecycle, HIV-1 is not able to infect quiescent T cells effi-
ciently [36-39]. Hence, latently infected resting memory T
cells may be generated when HIV-1 infected actively repli-
cating antigen-stimulated cells survive long enough to re-
vert back to a resting memory state and differentiate into
long-lived (half-life of ~44 months) resting memory T cells
[40-42]. Unfortunately, to date there is no experimental
evidence in vivo that can tell us if the latent cells have
been directly infected or reversed to the quiescent state
with the integrated provirus. The issue is complicated by
the fact that the frequency of infected resting memory
CD4+ cells is very low in vivo. The frequency of latently
infected cells, expressed in terms of infectious units per
million resting CD4+ T cells, is determined using Poisson
statistics and is on the order of 0.1-10 infectious units per
million resting CD4+ Tcells in most patients on long term
cART [28,43,44].
Although the existence of a stable latent reservoir in
resting CD4+ T cells is clearly established, evidence for
additional reservoirs comes from a detailed analysis of
residual viremia. The residual viremia in some patients
is dominated by oligoclonal populations called predom-
inant plasma clones that are rarely found in circulating
CD4+ T cells [22,45-47]. This phenomenon has sug-
gested the existence of a second reservoir for HIV-1 in a
cell type capable of proliferating after infection. Tissuemacrophages, primary targets of HIV-1 infection, could
be the source of these persistent oligoclonal HIV-1 pop-
ulations. Indeed, cells belonging to the monocyte/macro-
phage lineage, are one of the major persistent HIV-1
reservoirs. In these cells, viruses are generally not com-
pletely silent but maintain a low level of replication. In
contrast to T cells, HIV-1 infection is less cytopathic to
these cells; it even extends their lifespan and makes
them more resistant to apoptosis. To prove that macro-
phages function as a reservoir, studies of HIV-1 infection
of these cells in various tissues will have to be performed
in cART-treated patients who have had prolonged sup-
pression of viremia.
Naïve T cells have also been demonstrated to contain
latent proviruses [12,48,49]. HIV-1 DNA persists in
naïve CD4+ T cells in patients on suppressive cART, al-
though the frequency of infection is approximately 1–2
logs less than in memory CD4+ T cells [12]. The infec-
tion of naïve T cells, which are quiescent in nature, could
be explained by their transient partial activation, such as
under the influence of cytokines or during thymopoiesis,
but they eventually return back to the quiescent (G0)
phenotype [48-50]. The HIV-1 DNA concentration has
been shown to be similar in CD31+ naïve CD4+ T cells
(enriched for recent thymic emigrants) and CD31- naïve
CD4+ T cells (naïve cells that have undergone homeo-
static proliferation) both prior to and following cART
[48,51]. The S. Lewin’s group has shown that the abso-
lute number of infected naïve CD4+ T cells (expressed
as HIV-1 DNA copies/ml of blood) in fact increases fol-
lowing cART, suggesting that in the setting of cellular
proliferation, the reservoir of infected naïve T cells may
expand over time [48].
Patients infected with HIV-1 present hematopoietic ab-
normalities, which are caused by HIV-1 infection of the
bone marrow [52]. Hematopoietic progenitor cells (HPC)
have been proposed as a reservoir. A recent study has
shown that HIV-1 infects multipotent HPCs and that
latent HIV-1 infection is established in some of these
HPCs [53]. A follow-up study indicated that CD133+
cord-blood-derived cells were susceptible to in vitro infec-
tion, but only with X4 tropic virus [54]. However, more re-
cent studies of HPCs in patients on cART have used more
rigorous purification of CD34+ cells and have not detected
HIV-1 DNA by PCR and therefore not confirmed latent
infection of HPCs [55,56]. Further studies will therefore
be necessary to determine whether HPCs could constitute
a reservoir.
Anatomic sites of HIV-1 persistence
The central nervous system (CNS)
An important anatomical site for the HIV-1 reservoir is
the CNS, where HIV-infected cells are continuously
replenished by circulating infected monocytes. These
Van Lint et al. Retrovirology 2013, 10:67 Page 6 of 38
http://www.retrovirology.com/content/10/1/67monocytes cross the blood–brain barrier and differentiate
into macrophages and microglial cells. Within the CNS,
HIV-1 infection is detected principally in perivascular
macrophages and microglial cells [57]. Integrated HIV-1
DNA has also been found in astrocytes from the brains of
HIV-infected patients [58], and is associated with HIV-
associated dementia [59]. However, it may be important to
extend these studies, performed in viremic patients, by
studies of astrocytes in patients on suppressive cART. The
blood–brain barrier, which restricts entry of cytotoxic T
cells and does not allow free flow of anti-HIV-1 drugs, re-
duces the impact of immune responses and cART on
CNS-localized HIV-1 viruses [60,61]. The significance of
the CNS viral reservoir is still debated, since the overall
share of CNS-derived viruses in persistent viremia appears
to be negligible [62].
The gut-associated lymphoid tissues (GALT)
Another important HIV-1 reservoir is in the GALT,
where 5–10 times more HIV-1 RNA than in peripheral
blood mononuclear cells can be recovered [16,63].
Moreover, the addition of Raltegravir to patients on sup-
pressive cART results in a non significant decrease in
unspliced HIV-1 RNA in the ileum, potentially consist-
ent with ongoing replication at this site [21]. Of note, a
recent report has described a lack of evolution in the
proviral sequences from recto-sigmoid biopsies [23], re-
sults that are inconsistent with continuous viral replica-
tion in this site.
Lerner et al. [64] have shown that, in three patients who
initiated cART during acute infection, there was no phylo-
genetic relationship between the HIV-1 RNA sequences
from the rebound virus and HIV-1 DNA from the gastro-
intestinal tract tissue, suggesting that the gastrointestinal
tract is not the primary source of rebound viremia after
cART interruption cessation. However, these data cannot
exclude the possibility that a minor population of the
gastrointestinal tract contributes to the rebound of viremia.
Models of latency
To develop strategies towards a cure, the precise mo-
lecular mechanisms responsible for HIV-1 latency and
reactivation have to be studied in the more valuable
models. Unfortunately, the study of latency in vivo has
been hampered by the scarcity of latently infected cells,
by their difficult enrichment due to the lack of a specific
viral marker on the surface thus complicating their isola-
tion from non-infected counterparts and by the high
background rate of defective integrated proviruses. Con-
sequently, most of the biochemical studies concerning
the molecular aspect of HIV-1 latency until very recently
were performed using latently infected transformed cell
lines. However, the quiescent phenotype of the latently
infected CD4+ T cells found in vivo is substantiallydifferent from the constitutively activated and proliferating
nature of infected cell lines. Since these cell line models
do not accurately represent the quiescent cellular environ-
ment of primary latently infected cells in vivo, the devel-
opment of improved models ex vivo is an important goal
for HIV-1 research. Resting memory CD4+ T cells, the
major reservoir of latent HIV-1, can be subdivided in cen-
tral memory T cells (TCM: CCR7+; CD27+) and their de-
rivatives after TCR engagement called effector memory T
cells (TEM: CCR7-; CD27-) (for a review: [65]). Subsets of
TEM are further characterized by the expression of CCR5,
IL-12betaR and intracellular IFNgamma (Th1) or CRTH2
and intracellular IL-4 (Th2). TCM and TEM are CD45RO,
while naïve cells express CD45RA. Chomont and collabo-
rators have reported that TCM, together with a subset of
cells with functional and transcriptional characteristics
that are intermediate between those of TCM and TEM
called transitional memory T cells (TTM), are the major
reservoir of latent HIV-1 [12]. TEM, naïve T, or terminally
differentiated T cells, which are equally susceptible to
HIV-1 infection, are not involved in long-term latency
during cART. Recent years have shown an effort to estab-
lish an experimental system of HIV-1 latency that repre-
sents a complete recapitulation of the biologic state of the
latent cell reservoir in vivo. These systems would be very
important for the rational design of drugs to target HIV-1
latency. However, there are inherent difficulties for a uni-
fied model system given the presence of multiple cell types
where the virus can establish latency and the variety of
mechanisms that lead to latency and reactivation. In this
context, many laboratories have therefore come up with
several informative primary cell-based model systems. In
addition to ex vivo cellular models, in order to study the
properties of reservoirs in vivo, models in mice and in pri-
mates have been developed.
In vitro models
Most studies of HIV-1 latency have been conducted
using latently infected transformed cell lines. However,
recent progress in the field allowed the generation of
models of latently infected primary lymphocytes.
Latently infected transformed cell lines
The study of HIV-1 latency in transformed cell has re-
vealed many insights into the mechanisms of HIV-1 la-
tency, despite the fact that establishment of latency in
such systems is often linked to mutations in viral genes
or to an effect specific to the site of integration, perhaps
not uniformly representative of the quiescent nature of
resting CD4+ T cells in patients. Indeed, each latently
infected cell line possesses a different HIV-1 provirus
(full-length or not) and may contain one or more copie
(s) of the integrated provirus in different integration sites
or epigenetic environments. Firstly, several models have
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1 features of the LTR/Tat axis from models carrying a
full-length provirus. For example, the Jurkat E4 cells and
Jurkat bearing an integrated HIV-1 mini-virus are T-
lymphoid Jurkat cells containing one single copy of the
integrated provirus. However, E4 Jurkat cells possess a
fragment of the HIV-1 pNL4-3 (containing tat, rev, env
and vpu) and a short-lived green fluorescent reporter
protein (d2EGFP) in place of the nef gene [66,67] The
Jurkat cells bearing an integrated HIV-1 mini-virus
posses an HIV-1 reporter mini-virus, where luciferase is
produced from the HIV-1 5’LTR as an in-frame fusion
with p24gag [68].
Secondly, other models have been proposed that are based
on full-length proviruses including ACH2, the inducible
HIV-rtTA variant, J-Lat T cell lines and U1 promonocytic
cell lines. The ACH2 T-cell line [69] and the promonocytic
U1 cell line [70,71] show minimal constitutive expression of
HIV-1 genes, but a marked activation of viral gene expres-
sion following treatment with cytokines or mitogens. How-
ever, these models present mutations in Tat (U1) [72] or in
its RNA target TAR (ACH2) [73], which have been demon-
strated to be causative of the latent phenotype of the provi-
ruses integrated in these two cell lines. Ben Berkhout's
laboratory has developed stable cell lines containing an
HIV-rtTA variant (in which the Tat/TAR axis transcription
motifs have been inactivated and replaced by the inducible
Tet-ON system [74]). The HIV-rtTA provirus is completely
doxycycline-dependent for virus production, it contains the
original transcription factor binding sites in the HIV-1
5'LTR, and infected cells have been obtained without selec-
tion steps avoiding any bias towards activation markers [75].
However, the implications of the Tat/TAR axis in reactiva-
tion cannot be analyzed. More recently, J-Lat cell lines were
developed with an HIV-1-based vector containing an intact
Tat/TAR axis [76]. These cells whose unique provirus carries
the coding sequence for the green fluorescent protein (GFP)
replacing the nef gene were selected for a lack of GFP ex-
pression under basal conditions [76]. J-Lat cells allow for the
rapid assessment of HIV-1 transcriptional activity by
cytometric detection of GFP epifluorescence. Consequently,
the latently infected transformed cell lines are still useful to
study and understand the basic mechanisms governing
HIV-1 latency. The first models allow principally the study
of HIV-1 promoter activity. The second category permits a
complete study of the molecular mechanisms of latency
with the influence of produced viral proteins on the HIV-1
promoter but also on host genes.
Interestingly, the J. Karn’s lab has recently generated a
HIV-1 latently infected microglial cell line named
CHME-5 [77]. To this end, the CHME-5 cell line (pri-
mary fetal human microglial cells immortalized with the
SV40 large T antigen [78]) was infected with vesicular
stomatitis virus G (VSVG)-pseudotyped HIVs bearing afragment of HIV-1pNL4-3, containing tat, rev, env, and
vpu, plus nef adjacent to the reporter gene d2EGFP
inserted next to env. GFP + cells were next selected by
FACS, and further cultured and allowed to enter into a
latent state for 4 weeks. Latency of the CHME-5 cell
line was characterized by reactivating expression and
evaluating nuclear translocation of NF-kappaB [77].
Latently infected primary cells
Many laboratories have developed new ex vivo experi-
mental primary human CD4+ T cell-based model sys-
tems to study HIV-1 latency in a more physiological
context (reviewed in [79,80]). Several groups have
attempted to mimic in vitro the infection of activated
CD4+ T cells, with HIV-1 or HIV-1 derived vectors,
followed by the transition of these infected cells to a
resting state to establish latency in memory CD4+ T
cells. These cells are difficult to generate and maintain
because most CD4+ T cells die soon after activation if
not continuously cultured in the presence of specific cy-
tokines. This results in few cells that have transitioned
to a quiescent state and contain integrated HIV-1 that
can be used for further study. Culturing of CD4+ T cells
in the presence of cytokines, such as IL-2 or IL-7, in-
creases their survival and allows time (several weeks) for
more cells to transition to a memory state with inte-
grated HIV. However, IL-2 and IL-7 have been impli-
cated in the reactivation of latent HIV-1 [81-83].
Therefore, these cytokines must be used at a concentra-
tion that can maintain CD4+ T cells in culture without
reactivating latent HIV. Alternatively, activated and
HIV-infected CD4+ T cells can be maintained in culture
and allowed to transition back to a resting state in the
absence of cytokines by utilizing strategies, such as
transduction with anti-apoptotic proteins or co-culture
with feeder cell lines [84-86]. All these strategies lead to
more viable cells that have been infected and returned
to a resting state, allowing for HIV-1 latency to be stud-
ied in a physiologically relevant setting.
The first model of HIV-1 latency in primary lympho-
cytes was developed by Sahu et al. [84] and uses a
replication-competent virus for the infection. The feeder
cell line H80 (a brain tumor-derived cell line) promotes
cell survival in the absence of any cytokine and allows
the production of long-lived, mostly central memory
CD4+ T cells. However, despite being phenotypically
similar to resting cells in many respects, a significant
fraction of this population continues to express the early
activation marker, CD69, suggesting that these cells are
not completely resting. In J. Karn’s laboratory, Tyagi
et al. [86] developed a model of latency in which cells
are infected with VSV-G-pseudotyped, HIV-1 vectors
that lack env and encode a fluorescent marker in place
of nef. Interestingly, they use HIV-1 vectors that express
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that permits a quicker establishment of the latent state.
This model leads to a relatively homogeneous popula-
tion of central memory CD4+ T cells, which are not
completely resting since they continue to express signifi-
cant levels of the late activation marker, CD25 (CD69
expression is not measured). Marini et al. [87] have de-
veloped a primary latency model presenting the advan-
tage of using a replication-competent wild type HIV-1.
The majority of cells exhibits a central memory pheno-
type and is negative for CD25 (CD69 expression is not
shown) but is larger and more granular than freshly iso-
lated CD4+ T cells, suggesting that cells may not be
completely resting. A disadvantage of this model is the
requirement for IL-7, which has been shown to reacti-
vate HIV-1 in latently infected cells [83,88]. Bosque and
Planelles [89,90] developed a model in which cells are
infected with an envelope-deficient HIV-1 virus that is
pseudotyped with HIV-1 Env, thus limiting infection to a
single round. Isolated CD4+ T cells were activated first
with αCD3/αCD28 antibodies in the presence of IL-2
and then were cultured for several days in three different
conditions that produced Th1-helper, Th2-helper, and
nonpolarized CD4+ T cells [91]. Biochemical analysis in-
dicated that the Th1 and Th2 populations closely resem-
bled both effector memory and central memory CD4+ T
cells, in vivo, while the nonpolarized population more
closely resembled central memory CD4+ T cells. How-
ever, activation markers such as CD25 and CD69 were
not assessed before reactivation, giving no indication if
these cells were resting or active. Finally, Siliciano and
collaborators [85,92] increase cell survival in their model
by transduction of a lentivector to express BLC2 prior to
primary cells activation and expansion by αCD3/αCD28
antibodies and IL-2. Subsequent infection with a HIV-1
vector lacking several genes (including gag, vif, vpr, vpu
and env) and encoding GFP in place of nef, an establish-
ment of latency allowed the screening of a small library
of random drug-like molecules for anti-latency com-
pounds. This model generates effector memory cells ex-
pressing high levels of CD45RO and low levels of CCR7.
A small fraction of them still expresses CD69 and CD25.
At variance with the infection of activated primary cells
it is possible to infect directly resting (not activated) CD4+
T cells [30,34,35]. However, this is an inefficient process
owing to several blocks imposed by the cellular environ-
ment of resting T cells (including lack of dNTPs needed
for reverse transcription, a lack of ATP needed for nuclear
import of the viral DNA, as well as a restrictive cortical
barrier). Swiggard et al. [34] used spinoculation to effi-
ciently deliver large quantities of replication competent
HIV-1 virions to freshly isolated resting CD4+ T cells (a
mixture of naïve, TCM and TEM cells) in the absence of
any activating stimuli. Integration occurred resulting inlatently infected cells, albeit at a much lower frequency than
activated CD4+ T cells. Alternatively, Saleh et al. [30] have
first stimulated freshly isolated resting CD4+ T cells (naïve/
TCM/TEM cells) from uninfected donor blood with the
CCR7 (a lymphoid organ homing receptor) ligands, CCL19
and CCL21. These chemokines induce neither CD69 nor
CD25 expression, but do increase the susceptibility of rest-
ing CD4+ T cells to infection by a replication-competent
HIV-1 virus. Interestingly, chemokine-induced changes in
the actin cytoskeleton that are involved in cell migration
appear to be sufficient to allow HIV-1 integration inde-
pendently of cell activation [32]. Recent results also showed
that memory T cells are more sensitive to chemotactic
stimulation,which greatly facilitated HIV-1 infection [93].
Hence, there might be a pathway of direct infection of rest-
ing T cells also in vivo during normal chemokine-directed
recirculation of CD4+ T cells between blood and tissue.
More recently, by using novel reporter viruses, the W.
Greene’s group [35] described an improved version of the
primary CD4+ T-cell model originally developed in the
O’Doherty’s laboratory [34]. The Green’s model allows the
study of latency with replication-competent proviruses in
all subsets of CD4+ T cells. In addition to the GFP re-
porter virus that measures the number of cells in which
the latent HIV-1 provirus is successfully reactivated, the
Green’s lab has created a luciferase-expressing virus that
measures overall levels of transcriptional reactivation of
latent HIV-1. Importantly, they also generated a novel
mCherry-luciferase dual reporter HIV-1 virus to assess
simultaneously the number of cells containing reactivated
latent provirus in response of a specific inducer (mCherry)
and the magnitude of the response within the entire popu-
lation (luciferase) [35].
In addition to primary CD4+ T cell models, the Collins’s
group has generated an ex vivo model for establishing la-
tency in progenitor cells derived from human umbilical
cord or bone marrow [94]. CD133+ cells were isolated by
magnetic separation and infected with pseudotyped HIV-1
ΔEnv encoding a reporter. Three days after infection, ac-
tively infected cells expressing the reporter protein were re-
moved and the remaining cells were resuspended in media
with an integrase inhibitor to ensure that increases in re-
porter gene expression would derive solely from the reacti-
vation of the integrated virus. HIV-1 could establish a
latent infection in all of the subsets of HPCs that were ex-
amined, including an immature population that includes
hematopoietic stem cells and multipotent progenitors.
These cells could be reactivated by TNFalpha, SAHA, but
not HMBA or 5-aza-2'-deoxycytidine. Although this latter
model is preliminary, it appears that differences exist in the
establishment of latency in HPCs versus memory T cells
that should be analyzed in more detail.
After years when the only experimental models for
HIV-1 latency were a series of transformed cell lines
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new phase with a variety of primary cell-based models. Al-
though it is clear that current research on HIV-1 latency
requires such models, the choice of the right system re-
mains difficult. A fundamental issue is that we still don’t
know how HIV-1 latently infected resting memory T cells
are established in vivo. Either route of infection, direct or
after reversal to the quiescent state are plausible and can
be recapitulated in vitro. Since each route may impact on
the chromatin environment of the integrated virus, it is
likely that the results of experiments aimed at understand-
ing the mechanisms of latency and reactivation will be af-
fected. Another non-trivial aspect to consider is the length
of the experiment. Ex vivo activation of primary cells, their
infection and induction of latency is a lengthy process that
takes weeks while direct infection is much quicker. In
addition to obvious practical reasons, long term cell cul-
ture might induce changes in the chromatin environment
of the provirus that do not necessarily mimic the hypo-
thetical in vivo situation. On the other hand, techniques
such as spinoculation, where a great quantity of virus is
forced to infect a resting cell, are not physiological as well.
To conclude, while these primary cell-based models
have several attractive features including the ability to rap-
idly establish latency in memory CD4+ T cells, it will be
important to test each model side-by-side with the others.
Only by carefully comparing results from the different
models to results obtained with cells isolated from blood
of cART-treated HIV-infected patients will it be possible
to identify meaningful in vitro models for in vivo HIV-1
latency.
Ex vivo cultures of cells from patients
Viral outgrowth using resting CD4+ T cells isolated from
cART-treated aviremic HIV-infected patients seems to
be the gold-standard tool for screening and evaluating
anti-latency drug candidates, although it is a difficult
and costly one. In some of these systems, latently
infected cells were treated with a drug candidate to in-
duce virus production, and viral progeny was amplified
through co-culture with allogenic, activated, CD8+ de-
pleted PBMCs and in presence of IL-2 [95,96]. Import-
antly, in contrast to such systems, the Van Lint’s group
[97,98] performed ex vivo cultures of purified patient
cells in the absence of both added IL-2 and allogenic
stimulation (i.e. co-culture with PBMCs from an unin-
fected individual) to avoid extensive nonspecific T-cell
activation and proliferation, that may result in the amp-
lification of the genomic viral RNA level. Although as-
says of resting CD4+ T cells obtained from patients are
excellent systems for validating the anti-latency activity
of drug candidates, a whole-animal system would allow
for a more complete evaluation of reservoirs and poten-
tial therapeutic interventions.In vivo models in mice and in nonhuman primates
Limitations of human clinical studies, especially invasive
sampling of multiple reservoirs sites, make it imperative
to develop analogous and tractable animal models to
carefully characterize viral reservoirs and to rigorously
test the efficacy of novel approaches and their effects on
tissue reservoirs. HIV-1 cannot be studied in normal
mice due to limited species tropism of the virus.
Through the pioneering efforts of many investigators,
humanized mice are now routinely used to rapidly ad-
vance HIV-1 research. The major humanization proto-
cols and contributions to HIV-1 research of each models
were reviewed in [99]. Briefly, unlike transgenic mice,
models of severe combined immune-deficienthumanized
mice (SCID-hu, [50,100,101]) are not genetically manip-
ulated to express human proteins involved in different
aspects of the HIV-1 life cycle. Rather, SCID-hu mice
models are based on transplantation into immune-
deficient mice of either human tissues or hematopoietic
stem cells. More specifically, the CB17-SCID-hu mice
model transplanted with human fetal thymus and liver
tissues under the kidney capsule, allowed the study of
thymic infection but there was no systemic reconstitu-
tion of the immune system and sites of potential infec-
tion were therefore limited [50]. Moreover, since most of
the cells generated in this model were naïve, memory
cell infection was more difficult to study. Newly devel-
oped humanization protocols can overcome some of
these limitations: both NOD/SCID BLT mice [99] and
hu-Rag2−/− γc−/− mice [102] reconstitute better the hu-
man immune system as well as mucosal tissues by trans-
plantation of bone marrow, liver and the thymus under
the kidney capsule and by transplantation of bone mar-
row following irradiation, respectively. In both models,
resting memory CD4+ T cells constitute the predomin-
ant human T cell population. Moreover, it has been
recently demonstrated that cART in HIV-1-infected hu-
Rag2−/− γc−/− mice recapitulates some aspects of cART
in humans [103]. Complete suppression of viremia on
cART and viral rebound following cART discontinuation
were observed, suggesting the presence of persistent in-
fection in this model [103].
Of note, Murphy et al. have recently reported findings
consistent with feline immunodeficiency virus (FIV) la-
tency in peripheral blood CD4+ T cells isolated from
chronically infected cats [104]. This could represent a
valuable alternative to primates for the study of HIV-1
latency.
The nonhuman primate models are other important
models for HIV-1 cure research (reviewed in [105]).
Several similarities between HIV-1 and pathogenic SIV
(Simian Immunodeficiency virus) infection of macaques
exist including chronic immune activation, mucosal im-
mune dysfunction, microbial translocation and high levels
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nonhuman primate models provide real opportunities for
several reasons: (i) identity, dose, and route of virus chal-
lenge are known (ii) various clinical parameters such time
of infection or duration of cART can be controlled (iii)
active and persistent reservoirs can be fully characterized
(iv) testing of “risky” interventions is possible. Longitudinal
collections of blood/tissue, as well as elective necropsy are
available for determining virological and immunological pa-
rameters. cART therapy has been modeled using a larger
number and variety of anti-retrovirals in nonhuman pri-
mates [106,107]. Moreover, an animal model for a func-
tional cure has been developed in rhesus macaques using
the SIVagm.sab92018 strain [108]. It allows the study of
virological and immunological events that may lead to the
infection control both in blood and tissues [108]. Remark-
ably, Shytaj et al. recently reported complete viral suppres-
sion of SIVmac replication in rhesus macaques by a potent
multidrug combination [109]. This is an important step in
developing an animal model for HIV-1 cure research be-
cause it parallels the effects of antiretroviral therapy in
HIV-infected humans. Without complete suppression, test-
ing of therapeutic strategies to reduce viral reservoirs is
confounded by ongoing cycles of viral replication that can
replete such reservoirs.
Since none of the current animal models perfectly re-
produce HIV-1 infection and cART, it is likely that sev-
eral different models will be needed to understand virus
persistence, latency, reactivation, and eradication.
Regulation of HIV-1 gene expression and latency:
mechanisms and pharmaceutical targeting
Highly relevant to the transcriptional state of HIV-1 pro-
virus is the chromatin environment that surrounds the
viral promoter. Therefore, a big effort is being put in the
definition of the integration site-selection preferences of
HIV-1 and in the chromatin landscape of the integration
site. Since most of the studies for HIV-1 latency have been
conducted in T cells, we will focus on those keeping in
mind that there might be differences in the mechanisms
of latency in other infected cells such as monocytes/mac-
rophages and myeloid dendritic cells.
Integration-site selection and transcriptional interference
Integration into the host genome is a hallmark of retro-
virus infection. After reverse transcription in the cyto-
plasm the pre-integration complex (PIC) travels to the
nucleus where the linear viral DNA is pasted into chro-
matin. HIV-1 integration is catalyzed by the viral enzyme
integrase (IN).
IN operates in close association with the cellular co-
factor LEDGF/p75 (lens epithelium-derived growth fac-
tor). LEDGF/p75 tethers IN to the host cell chromatin
determining HIV-1 integration site distribution, protectsit from proteolytic degradation and stimulates its enzym-
atic activity [110]. Recently, another interactor of IN, the
hepatoma-derived growth factor related protein 2 (HRP-
2), has been demonstrated to partially complement
LEDGF/p75 activity in a LEDGF/p75 knockout cell line
[111]. However, another study showed residual integra-
tion in double LEDGF/p75 and HRP-2 knockouts indi-
cating that IN alone and/or other host factors may still
contribute to the integration specificity [112].
HIV-1 integrates into cellular DNA non-randomly.
Bushman and colleagues first demonstrated that HIV-1
integrates preferentially into active cellular genes of
transformed cell lines [113,114]. This observation was
confirmed in infected CD4+ T cells from patients
[115,116]. LEDGF/p75 is a major determinant of HIV-1
integration into transcription units [117,118]. Inter-
action with LEDGF/p75, together with the local remod-
eling of chromatin through the interaction with INI1
(a subunit of the SWI/SNF chromatin-remodeling com-
plex), appears to be required locally for integration
[119]. However, also the topological organization of chro-
matin within the nucleus may play a role in target site se-
lection [15]. Depletion of nuclear pore proteins such as
RanBP2/Nup358 and the karyopherin Transportin-
3/TNPO3 resulted in marked alterations in the distribu-
tion of HIV-1 integration sites, providing a link between
nuclear entry and integration site targeting [120]. In agree-
ment, the sub-nuclear distribution of integrated HIV-1 in
latent cells occurs predominantly at the nuclear periphery
[121]. We can envisage that PIC engagement of the nu-
clear pore addresses HIV-1 integration into active genes
localized in its proximity. How does the latency phenotype
relate with this topological localization remains open.
The paradox of HIV-1 integration in active genes while
being transcriptionally silent stimulated the molecular
investigation of the phenomenon. Transcriptional inter-
ference has been proposed to explain HIV-1 promoter
repression when integrated into introns of highly
expressed genes. Transcriptional interference refers to
the direct negative impact of one gene on another in cis.
Convergent antisense transcription results inevitably in
inhibition while sense transcription may be inhibitory or
stimulatory. Peterlin and coworkers demonstrated HIV-1
promoter occlusion and generation of chimeric tran-
scripts with the endogenous gene in sense integrations
[122]. At odds, HIV-1 expression could be enhanced ra-
ther than repressed in sense orientation integrations of
HIV-1 generated by homologous recombination [123].
However, a bias towards integration in the sense orienta-
tion with respect to the endogenous gene has been ob-
served by the same group in an ex vivo model system of
HIV-1 post-integrative latency [124]. This preference
was not observed for acutely infected cells suggesting
that sense orientation may provide a more repressive
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gent orientation. Recently, Jordan and colleagues explored
this phenomenon further and identified chromatin re-
assembly factors recruited after RNA polymerase II
(RNAPII) transcription that repress the integrated cryptic
HIV-1 promoter [125]. The picture may be more compli-
cated since it has been observed that the HIV-1 genome
can insert in a gene that is also repressed by Tat and this
could be an advantage for the virus during transcriptional
reactivation [126]. In addition, it has also been shown by
allele-specific single cell in situ hybridization that tran-
scription of the provirus and of the endogenous gene in
which it is integrated may coexist at the same time in the
same genomic location.
Role of cellular factors
Molecular regulation of HIV-1 transcription is a multifa-
ceted process dictated in part by the abundance of cellu-
lar transcription factors that induce or repress HIV-1
promoter activity and by the viral Tat protein. HIV-1
promoter activity is also tightly linked to the level of ac-
tivation of its host cell. Mechanisms that maintain HIV-
1 latency in vivo are incompletely understood. It is
widely accepted that the lack of active forms of key cel-
lular transcription factors (NF-kappaB, NFAT, STAT5,
Figure 2) is one element involved in repression of initi-
ation and elongation, respectively, of viral transcription
in resting CD4+ T cells (reviewed in [3]). The presence
of host transcription repressors (i.e. DSIF, YY1, CTIP2,
c-myc, CBF-1, p50 homodimers, Figure 2) may also con-
tribute to HIV-1 latency.
The 5'LTR functions as the HIV-1 promoter and con-
tains DNA binding sites for several ubiquitously expressed
cellular transcription factors, such as Sp1 and TFIID, and
inducible transcription factors, including NF-kappaB,
NFAT and AP-1. Of note, the Berkhout’s group has re-
cently found that the ability of HIV-1 to establish a latent
infection is controlled by a four-nucleotide AP-1 element
just upstream of the NF-kappaB element in the viral pro-
moter [127]. Indeed, deletion of this AP-1 site deprived
HIV-1 of the ability to establish a latent HIV-1 infection.
Moreover the extension of this site to a 7 nucleotide AP-1
sequence promoted latency establishment, suggesting that
this promoter region represents a latency establishment
element. Given that these minimal changes in a transcrip-
tion factor binding site affect latency establishment to
such a large extent, their data support the notion that
HIV-1 latency is a transcription factor restriction
phenomenon. Indeed, HIV-1 transcription is tightly
coupled to the cellular activation status because both NF-
kappaB and NFAT are sequestered in the cytoplasm of
quiescent T cells and recruited to the nucleus following T-
cell activation. The protein kinase C (PKC) pathway lead-
ing to the activation of NF-kappaB, NFAT and AP-1 is oneof the most important pathway in HIV-1 reactivation
(reviewed in [3,128]).
In addition to the binding sites for inducible transcription
factors located in the HIV-1 promoter, three AP-1 binding
sites have been identified in the coding region of the viral
genome, more precisely in a region of the pol gene called
fragment 5103 [129]. Van Lint and Verdin have previously
described an important intragenic region in the HIV-1 gen-
ome, whose complete functional unit is composed of the
5103 fragment, the DNase I-hypersensitive site HS7 and
the 5105 fragment [130-132]. The intragenic AP-1 binding
sites are fully responsible for the PMA-dependent enhancer
activity of fragment 5103 and recruit in vivo the AP-1 fam-
ily members c-Fos, JunB and JunD [133]. Moreover, infec-
tion of T-lymphoid Jurkat and promonocytic U937 cells
with wild-type and mutant viruses demonstrate that muta-
tions of the intragenic AP-1 sites individually or in combin-
ation alter HIV-1 replication. Importantly, mutations of the
three intragenic AP-1 sites lead to a decreased in vivo re-
cruitment of RNAPII to the viral promoter, strongly
supporting that the deleterious effect of these mutations on
viral replication occurs, at least partly, at the transcriptional
level [133]. Single-round infections of monocyte-derived
macrophages confirm the importance of the intragenic AP-
1 sites for HIV-1 infectivity [133].
Many inducers of the NF-kappaB pathway have been
considered for purging the latent reservoirs of HIV-1.
PKC agonists, including synthetic analogs of diac-
ylglycerol [134], ingenols [135], phorbol-13-monoesters
[136], a jatrophanediterpene (named SJ23B) [137], and
the two non tumorigenic phorbol esters prostratin
[138,139] and DPP (12-deoxyphorbol 13-phenylacetate)
[140], have proven capable of inducing HIV-1 transcrip-
tion in latently infected CD4+ T cells or in PBMCs from
cART-treated patients. PKC agonists downregulate the
expression of the HIV-1 receptor CD4 and the
coreceptors CXCR4 and CCR5 on the host cell surface
[135,141,142]. Therefore, these compounds exhibit in-
teresting bipolar properties as potential molecules to
purge resting T-cell latent reservoirs: they upregulate
the expression of latent proviruses and inhibit the
spread of newly synthesized viruses to uninfected cells
via downregulation of critical receptors necessary for
viral entry [143]. The phorbol ester prostratin activates
HIV-1 expression in latently infected lymphoid and mye-
loid cell lines and in primary cells [138-141,143-145] with
minimal effects on the immune system [144] and causes
minimal perturbation of cell cycle progression [145]. Like
bryostatin 1 and DPP, prostratin as a PKC activator ex-
hibits non-tumor-promoting activity. The non-mitogenic
property of prostratin, its remarkable dual role in activat-
ing HIV-1 latently infected reservoirs without spreading
infection, its relatively nontoxic behavior, and its ability to
act on different cell types make this drug an interesting
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tages, the use of prostratin (and DPP) in human clinical tri-
als awaits safety and toxicity studies in a suitable primate
model [146,147]. However, preliminary pharmacokinetic
studies are encouraging [138]. Furthermore, chemical syn-
thesis of this therapeutically promising natural compound
in gram quantities and at low cost was reported [148] open-
ing the access to numerous new analogs. Interestingly, a re-
cent study [149] has shown that nanoparticles loaded with
bryostatin target and activate primary human CD4+ T cells
and stimulate latent virus production in vitro from latently
infected J-Lat 8.4 and 10.6 cell lines and ex vivo from la-
tently infected cells in a humanized mouse model, SCID-
hu. Moreover, these authors suggest that specific targeting
of the nanoparticles to CD4+ T cells by incorporating an
anti-CD4 antibody could be an attractive perspective. Inter-
estingly, methamphetamine, a potent CNS stimulant used
by certain drug abusers, was recently shown to directly in-
crease HIV-1 LTR activity in vitro in human microglial cells
(the primary host cells for HIV-1 in the CNS), through an
NF-kappaB-dependent mechanism [77]. This finding could
explain the more severe HIV-associated neurodegeneration
in HIV-infected individuals who abuse methamphetamine
than in HIV-infected individuals who do not abuse drugs
[150,151]. Because NF-kappaB is a “master regulator” of so
many key responses in mammals, inducers of the NF-
kappaB pathway for purging the latent reservoir will prob-
ably cause side effects. Therefore, a strong but short burst
of NF-kappaB activity could be less deleterious until NF-
kappaB activation is sufficient to trigger an initial Tat pro-
duction, which will then fully induce HIV-1 expression. In
this regard, a study has demonstrated that a protein se-
creted by the bacterium Massilia timonae efficiently
reactivates latent HIV-1 by producing a strong and short
activation of NF-kappaB [152]. Other members of the NF-
kappaB pathway can also be targeted for HIV-1 transcrip-
tional activation. One of such examples is the
IkappaBepsilon protein [153]. Five IkappaB proteins have
been described in humans that regulate NF-kappaB signal-
ing. IkappaBs bind NF-kappaB dimers in the cytoplasm,
preventing the NF-kappaB proteins from translocating to
the nucleus to regulate gene expression. Some NF-kappaB
dimers exhibit binding preferences for certain IkappaBs
[154]. Thus, the relative abundance of certain IkappaB pro-
teins within the cell may affect the availability of specific
NF-kappaB dimers for activation. Moreover, different cell
types produce different complements of NF-kappaB dimers
[155]. IkappaBepsilon is expressed predominantly in T cells
of the thymus, spleen, and lymph nodes [156]. Therefore,
major sites and cell types of IkappaB epsilon expression co-
incide with some of the main reservoirs of HIV-1 latently
infected cells. These results may offer attractive therapeutic
advantages for HIV-1 activation because IkappaB epsilon is
not essential for mammalian growth and development.The group of A. Jordan has recently identified eight
molecules that reactivated latent HIV-1 by screening a
library of small molecules. One of them, 8-methoxy-6-
methylquinolin-4-ol (MMQO) reactivates HIV-1 in la-
tently infected J-Lat cell lines and in PBMCs from
aviremic cART-treated HIV-1 patients without causing
T-cell activation and with low toxicity. Interestingly,
MMQO produces Jun N-terminal protein kinase (JNK)
activation and enhances the TCR/CD3 stimulation of
HIV-1 reactivation from latency, but inhibits CD3-induced
IL-2 and TNF-alpha gene transcription. Moreover, MMQO
prevents TCR-induced cell cycle progression and
proliferation in primary T cells [157].
In addition to inducers of HIV-1 gene expression,
aloisine A or roscovitine have been shown to inhibit
HIV-1 replication when added after HIV-1 reactivation,
but inhibition by these compounds is not potent [158].
However, an inhibitor of JNK, called AS601245, has re-
cently been shown to strongly inhibit HIV-1 reactivation
by inhibiting AP-1 activation despite high levels of in-
duced NF-kappaB activation [158].
In addition to the PKC pathway, a recent study has
shown that depletion of the transcription factors YY1
significantly increases mRNA and protein expression
from the HIV-1 promoter [159]. Inhibition of the repres-
sive transcriptional factor YY1 could also be a promising
strategy in order to reactivate HIV-1.
Xing et al. have first demonstrated, in a Bcl-2-trans-
duced primary CD4+ T cell model, that Disulfiram
(DSF), a FDA-approved drug used to treat chronic alco-
holism, reactivates latent HIV-1 without inducing global
T-cell activation [160]. Based on this finding, DSF is cur-
rently being assessed in a clinical trial for its potential to
deplete the latent HIV-1 reservoirs in cART-treated pa-
tients (see below). Very recently, the group of J.W.
Mellors and N. Sluis-Cremer reported the mechanism
by which DSF, an inhibitor of acetaldehyde dehydrogen-
ase, reactivates latent viral expression [161]. This latter
study has shown that DSF reactivates HIV-1 expression
in the latently infected U1 cell line, but not in the
J89GFP or ACH2 cell lines. Interestingly, they found that
DSF significantly reduces PTEN (Phosphatase and
Tensin homolog, a negative regulator of the Akt signal-
ing pathway) protein levels in U1 cells and in resting
CD4+ T cells from HIV-negative donors, resulting in in-
creased phosphorylation of Akt and activation of the
Akt signaling pathway [161]. Pharmacological inhibitors
of Akt or of NF-kappaB (a downstream target of Akt)
block the latent HIV-1 reactivating activity of DSF. In
contrast, inhibitors of NFAT, of PKC and of JNK do not
affect DSF activity. Neither the J89GFP nor ACH2 cells
express PTEN, explaining the lack of DSF effect on HIV-
1 expression in these two cell lines [161]. In conclusion,
DSF could reactivate latent HIV-1 expression in vivo via
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and PTEN could be a regulator of HIV-1 latency in
cART-treated patients.
T cell factor 4 (TCF-4) is an additional transcriptional fac-
tor that inhibits HIV-1 replication [162-165]. TCF-4, a
member of the T cell factor/lymphoid enhancer factor
(TCF-LEF) family of transcription factors, is a downstream
effector of the canonical Wnt/beta-catenin pathway. It asso-
ciates with beta-catenin (a transcriptional coactivator) to
regulate the transcription of a diverse set of genes involved
in cell proliferation, differentiation, communication and sur-
vival. Binding of a Wnt ligand initiates a cascade of events
that results in destabilization of a multiprotein beta-catenin
destruction complex and accumulation of a stable,
hypophosphorylated beta-catenin that is able to translocate
to the nucleus and associate with a member of the TCF/LEF
transcription factors family. Within the nucleus, beta-
catenin displaces negative regulatory factors from TCF/LEF
and recruits cofactors to activate transcription of Wnt target
genes. Active Wnt/beta-catenin/TCF-4 signaling pathway
plays a significant role in repression of HIV-1 replication in
multiple cell targets, including peripheral blood lymphocytes
and astrocytes [162,163,166,167]. Recently, Henderson et al.
[168] have identified multiple TCF-4 binding sites in the
HIV-1 LTR. Deletion or mutation of the site presenting the
strongest association, in conjunction with beta-catenin or
TCF-4 knockdown in cells stably expressing a LTR reporter
construct, enhances LTR basal activity, but has no effect on
Tat-mediated transactivation [168]. TCF-4 and beta-catenin
at the LTR associate with the nuclear matrix binding protein
SMAR1, which likely pulls the HIV-1 DNA segment into
the nuclear matrix and away from the transcriptional
machinery, leading to repression of basal HIV-1 LTR tran-
scription [168]. Exploring the contribution of beta-catenin
/TCF-4 to HIV-1 latency might open novel avenues for anti-
latency therapies. In this regard, LiCl, an inhibitor of Wnt
signaling, has been recently shown to synergize with histone
deacetylase inhibitors (HDACI, valproic acid (VPA) or
SAHA) in inducing reactivation of the latent HIV-1 LTR in
a cell line model of HIV-1 latency (Rafati et al., 2012, Ab-
stract Retrovirology, 9 (Suppl1):O3)). The level of activation
of the latent LTR was found to correlate with the remodel-
ing of the repressive nucleosome nuc-1. Regulators of the
Wnt signaling pathway could provide an additional strategy
with which to promote reactivation of the latent LTR, par-
ticularly in combination with HDACIs.
A member of the Janus kinase (JAK)/signal transduc-
ers and activators of transcription (STAT) family, called
STAT5, has been demonstrated to play a both positive
and negative role in regulating HIV-1 transcription. By
using primary human CD4+ T cells transfected with a
HIV-1 LTR-driven reporter construct, the full-length
STAT5 factor has been reported to upregulate HIV-1
transcription by binding to putative STAT5 consensusbinding sites in the LTR U3 enhancer region [169].
STAT5A and STAT5B are activated by a broad spec-
trum of cytokines such as IL-2, IL-7, IL-15 and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) through JAK-mediated phosphorylation of a critical
tyrosine residue near the C-terminus, leading to the for-
mation of homodimers or heterodimers of STAT5A and
STAT5B, followed by nuclear translocation of the active
complex [170]. Interestingly, a C-terminally truncated ver-
sion of STAT5 (STAT5Δ), frequently detected as a domin-
ant isoform in leukocytes of HIV+ individuals [171], has
been shown to act as a repressor, rather than an inducer
of HIV-1 transcription and expression [172]. Indeed, the
Poli’s group has shown that the chronically HIV-1-
infected promonocytic U1 cell line mostly expresses
STAT5Δ compared to the infected T-lymphoid ACH2
cell line and that GM-CSF stimulation of U1 cells leads to
STAT5Δ binding to the LTR U3 region, resulting in a de-
creased recruitment of RNAPII to the HIV-1 promoter and
concomitant repression of viral gene transcription [172].
Moreover, they have very recently reported that, in U1 cells,
STAT5Δ interacts exclusively with the NF-kappaB p50 sub-
unit at the level of the nt −85 to −77 HIV-1 subtype B
STAT5 site, which overlaps with the nt −81 to -92nt NF-
kappaB binding site [173]. Furthermore, GM-CSF stimula-
tion of U1 cells promotes in vivo recruitment of p50 to
the viral LTR together with STAT5Δ and downregulates
HIV-1 transcription. Thus, cytokine-activated STAT5Δ/
p50 complexes could contribute to the maintenance of
HIV-1 latency in monocytic cells. In addition to STAT5,
some other cellular transcriptional repressors of HIV-1
(such as Staf50 [174]) exhibit regulatory function, which
is specific for human macrophages [175,176]. Interest-
ingly, IL-7 (a cytokine essential for maintenance of T
cell homeostasis) has been shown to induce the expres-
sion of latent HIV-1 proviruses in resting CD4+ T cells
from HIV-infected patients under cART treatment
without global T cell activation, via the JAK/STAT5 sig-
naling pathway [83].
In addition to transcription factors, specific restriction
factors exist to defend host cell against retroviral infec-
tion. A well-known restriction factor is APOBEC3G that
impairs the early phase of the HIV-1 life cycle and may
induce latency. Indeed, APOBEC3G strongly inhibits
HIV-1 replication in CD4+ T cells by inducing C to U
conversions in the viral strand DNA during reverse tran-
scription [177,178]. An inactive form of APOBEC3G can
be found in tissue resident naïve or memory CD4+ T
cells, which are permissive to HIV-1 infection [179]. In
parallel, a growing body of evidence suggests that many
members of the TRIM family of proteins constitute an
antiviral defense mechanism for the cell [180]. TRIM19
(better known as PML) has been implicated in the re-
striction of HIV-1 by recruiting Cyclin T1 to nuclear
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striction of HIV-1 by repressing the basal LTR activity inde-
pendently of its E3 ubiquitin ligase activity, of Tat and
NF-kappaB-responsive LTR elements [182]. In addition, the
group of Cereseto has proposed that TRIM28 inhibits HIV-
1 replication by suppressing acetylation of the viral
integrase during integration [183]. Moreover, a recent study
has reported that ZBRK1 (a KRAB-zinc finger) acts as a
transcriptional repressor of HIV-1 LTR in a TRIM28-
dependent manner [184]. Indeed, in conjunction with
TRIM28 and HDAC2, ZBRK1 suppresses HIV-1 LTR-
driven gene expression [184]. Importantly, in elegant stud-
ies by the Benkirane’s group and Skowronski’s group,
SAMHD1 was recently described as the restriction factor
that blocks HIV-1 infection of non-cycling myeloid cells
[185,186]. SAMHD1 is a dGTP-dependent deoxynucleotide
triphosphohydroxylase [187,188] that reduces the cellular
pool of dNTPs in differentiated, non-cycling myeloid cells
to levels below those required to support HIV-1 DNA syn-
thesis [188,189]. SAMHD1 also restricts HIV-1 replication
in quiescent resting CD4+ T cells by preventing completion
of reverse transcription, a finding that could have an im-
portant implication in our understanding of HIV-1-medi-
ated CD4+ T-cell depletion and establishment of the viral
reservoir [190,191].
Finally, the heat-shock chaperone Hsp90 was shown to
bind the HIV-1 promoter and to regulate its expression
and viral infectivity [192]. Hyperthermia induces Hsp90
recruitment at the viral LTR, leading to transcriptional
reactivation [193]. Since the viral genome exhibits
RNAPII pausing at its promoter and NELF-E depletion
results in increased viral transcription, it is possible that
Hsp90 targets the paused RNA polymerase located on
the HIV-1 promoter via NELF and, similar to several
genes reported in the work of Paro and collaborators,
affects release of paused polymerase from the viral
LTR [194].
Chromatin organization and epigenetic modifications
The chromatin organization and the epigenetic control
of the HIV-1 promoter are key elements in viral tran-
scriptional silencing. Previously, the Verdin’s group has
shown that two nucleosomes, namely nuc-0 and nuc-1,
are precisely positioned in the promoter region of HIV-1
in latently infected cell lines [131,195] and that nuc-1
(located immediately downstream of the transcription
start site) imposes a block to transcriptional elongation
(Figure 2). Following transcriptional activation, nuc-1 is
specifically remodeled [195,196].
Chromatin condensation is critical for the regulation
of gene expression since it determines the accessibility
of DNA to regulatory transcription factors. Euchromatin
corresponds to decondensed genome regions generally
associated with actively transcribed genes. By contrast,heterochromatin refers to as highly condensed and tran-
scriptionally inactive regions of the genome [197]. The chro-
matin condensation status can be modulated through a
variety of mechanisms, including posttranslational covalent
modifications of histone tails, ATP-dependent chromatin re-
modeling events and recruitment of repressive factors on
methylated DNA [198-200]. ATP-dependent chromatin re-
modeling complexes couple the hydrolysis of ATP to struc-
tural changes of the nucleosome. Histone modifications are
all reversible and mainly localized to the amino-terminal his-
tone tails. They include acetylation, methylation, phosphor-
ylation, sumoylation, ADP-ribosylation and ubiquitination.
In this review, we will focus on histone acetylation and
methylation, the most important histone marks for HIV-1
repression. These covalent modifications of histone tails in-
fluence gene expression patterns by two different mecha-
nisms [201]: (1) by directly altering chromatin packaging,
electrostatic charge modifications or internucleosomal con-
tacts might emphasize or reduce the access of DNA to tran-
scription factors (such as histone acetylation); (2) by
generating interactions with chromatin-associated proteins
(such as histone methylation). These modifications function
sequentially or act in combination to form the "histone
code" and serve as extremely selective recruitment platforms
for specific regulatory proteins that drive different biological
processes [202]. A description of the different classes of
chromatin-modifying enzymes is reviewed in [3]. Here, we
describe their importance in HIV-1 repression and their
possible therapeutic implications.
Histone acetylation
Histone acetyltransferases (HATs) and histone deacetylases
(HDACs) influence transcription by selectively acetylating
or deacetylating the ε-amino group of lysine residues in his-
tone tails. Generally, chromatin acetylation by HATs pro-
motes chromatin opening and is associated with active
euchromatin, whereas deacetylation by HDACs diminishes
the accessibility of the nucleosomal DNA to transcription
factors, thereby generating repressive heterochromatin
[203]. Moreover, histone acetylation marks enable the re-
cruitment of bromodomain-containing proteins, such as
chromatin remodeling complexes and transcriptions fac-
tors, which in turn regulate gene expression. The repressive
nucleosome nuc-1 is specifically remodeled following PMA
or TNFalpha treatment of the cells, coinciding with activa-
tion of HIV-1 gene expression [195]. This remodeling in-
cludes posttranslational modifications of histone tails. In
this context, Van Lint and Verdin reported for the first time
16 years ago that treatment of latently HIV-1-infected cell
lines with two HDAC inhibitors (HDACIs), trapoxin and
trichostatin A (TSA), induces viral transcription and the re-
modeling of the repressive nucleosome nuc-1 [196]. These
results indicated that one or several HDACs were bound to
the HIV-1 promoter under latency conditions and that
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enzymes played a role in the establishment and mainten-
ance of HIV-1 latency. This observation also indicated that
treatment of HIV-infected patients with HDACIs might be
of therapeutic value by forcing the reactivation of HIV-1 ex-
pression and the elimination of the latent HIV-1 reservoir
(“flushing hypothesis”) [80,196,204].
Later experiments revealed that transcriptional repres-
sors recruit HDACs to the HIV-1 promoter (reviewed in
[3], Figure 2). Following viral reactivation, acetylation of
histones and recruitment of HAT at the HIV-1 promoter
have been described by the group of Giacca [205]. To
date, numerous studies have demonstrated that HDAC1,
HDAC2 and HDAC3 are recruited to the HIV-1 LTR5’
and play an important role in viral latency [206-210]. In
microglial cells, Marban et al. showed that the corepres-
sor CTIP2 acts as a recruitment platform for HDAC1
and HDAC2 on the HIV-1 promoter, leading to a het-
erochromatin environment [207,211].
Recently, the group of Poli has shown that essential
amino acid restriction results in the transcriptional dere-
pression of silenced transgenes including the HIV-1 pro-
virus in T-lymphocytic cells [212]. This derepression
correlates with a significant downregulation of HDAC4.
These results indicate that HDAC4 behaves as a critical
regulator of exogenous transgene expression [212], sen-
sitive to amino acid starvation and suggest that HDAC4
pharmacological inhibition may be necessary to revert
HIV-1 transcriptional silencing and lead to reactivation
of latent HIV-1. In this context, recently, Xing et al. have
provided strong evidence that HDAC6-selective inhibitor
M344 is a potent antagonist of HIV-1 latency, acting by
increasing the acetylation of histones H3 and H4 in the
nuc-1 region of the HIV LTR [213].
HDACIs present several advantages as a potential in-
ductive adjuvant therapy in association with efficient cART
to purge latent reservoirs. They activate a wide range of
HIV-1 subtypes [204] without the toxicity associated with
mass T-cell activation, which would generate new target
cells for neo-synthesized viruses. HDACIs have been dem-
onstrated to repress the coreceptor CXCR4 in a dose-
dependent manner [214]. They act on a broad spectrum of
cell types; and therefore, in contrast to agents that specific-
ally induce T cells, they could target the different latent res-
ervoirs (macrophages, dendritic cells and other non-T
cells). The most important element regarding the thera-
peutic goal resides in the fact that HDACIs have been
safely administrated to patients for several years in other
human diseases: phenylbutyrate in beta-chain hemoglobin-
opathies such as beta-thalassemia and sickle cell anemia
[215,216] and VPA in epilepsy and bipolar disorders
[217,218]. More recently, SAHA (marketed as Vorinostat)
was approved by the Food and Drug Administration (FDA)
for treatment of cutaneous T-cell lymphoma [219].Givinostat and Panobinostat are currently in Phase I/II
clinical trials for relapsed hematological malignancies
[220,221]. Givinostat has been shown to be more potent
than VPA in terms of reactivation of HIV-1 expression
in vitro [222], while Panobinostat has been shown to
be at least 10 times more potent than Vorinostat
(reviewed in [223]).
The use of HDACIs as HIV-1 inducers has been well
characterized in several latency models and in resting
CD4+ T cells from cART-treated HIV-1-infected pa-
tients [97,204,222,224,225]. A series of such molecules
has been characterized in terms of HIV-1 reactivation
[210,226,227]. However, some groups have reported that
HDACIs have a lower reactivation potential in a primary
latency model [228] or in resting CD4+ T cells from
cART-treated HIV-1-infected patients [229] compared
to infected transformed cell lines. The first study was
performed in a model of primary T cells [228], which
might not reflect the in vivo situation. Indeed, a recent
clinical trial (see below) has shown that Vorinostat
reactivates HIV-1 in infected patients [230]. In the sec-
ond study [229], the concentration of HDACI used was
lower than the common concentration used in the nu-
merous studies that have previously tested the HIV-1 re-
activation potential of HDACI [226,231]. Moreover, their
finding indicates rather that HDACIs induce virus pro-
duction but from a restricted fraction of infected cells,
in agreement with the coexistence of different latency
mechanisms [98,99,232].
More recently, many other HDACIs have been evalu-
ated in vitro for their reactivation potential in latentlyHIV-
1-infected cells: ITF2357 [222], CG05 and CG06 [233],
NCH-51 [234] and MC1293 [235]. In order to identify
new compounds, several groups have performed high-
throughput screening. In this context, molecules such as
AV6 [236] or a range of Merck compounds [95] have been
highlighted. In parallel, another study has demonstrated
that butyric acid naturally produced from bacteria could
promote gene expression of latent HIV-1 [237]. The ef-
fects of these different compounds have yet to be con-
firmed in ex vivo cultures of resting CD4+ T cells from
cART-treated HIV-infected patients.
Latency is a multifactorial phenomenon: different levels
of transcriptional and epigenetic blocks are involved and
probably act in concert to silence HIV-1 transcription.
Attacking simultaneously different levels of latency should
be more efficient when viral eradication is the objective
since the combination of different types of compounds
could synergize in the reactivation of latently infected cells.
In this context, Van Lint’s group has reported for the first
time that HDACIs and NF-kappaB inducers synergistically
reactivate latent HIV-1 [204]. Mechanistically, this syner-
gism was associated with a delayed cytoplasmic reappear-
ance of the inhibitory protein IΚBalpha in response to
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to a prolonged intranuclear presence and DNA-binding ac-
tivity of NF-kappaB [238,239]. Next, the same group has
shown that the non-tumor-promoting NF-kappaB inducer,
prostratin, synergistically reactivates HIV-1 production
with HDACIs used in human therapies (such as VPA and
SAHA) in several postintegration latency model cell
lines as well as in ex vivo cultures of in CD4+ CD25-
CD69- HLADR- resting T cells isolated from blood
of cART-treated patients with undetectable viral load
[97]. Mechanistically, HDACIs prolonged and increased
prostratin-induced NF-kappaB activation and provoked, in
combination with prostratin, a more pronounced nucleo-
some remodeling in the HIV-1 promoter. This study con-
stitutes a proof-of-concept for the coadministration of two
different types of therapeutically promising HIV-1 inducers
together with efficient cART as a therapeutic perspective to
decrease the pool of latent HIV-1 reservoirs [97]. However,
in 40% of the cultures, this group could not detect any
viral outgrowth following treatment with prostratin and
HDACIs individually or in combination. This could result
from a stronger epigenetic control of some integrated
proviruses. Latter, Burnett and colleagues reported that
the same combination prostratin + SAHA synergistically
reactivates several HIV-1 subtypes including A, B, C, D
and F in primary CD4+ and Jurkat cell-based in vitro HIV-
1 latency models [240]. Another study has shown similar
results with the HDACI MC1293 in a latently infected cell
line but did not report testing of this HDACI in ex vivo cell
cultures from HIV+ patients [235]. Interestingly, another
non-tumor-promoting PKC inducer, bryostatin, has been
shown to activate MAPKs and NF-kappaB pathways and
to synergize with HDACIs to reactivate HIV-1 gene ex-
pression in latently infected J-Lat cell lines [241].
Histone methylation
While histone deacetylation generally contributes to tran-
scriptional repression, histone methylation can be either
linked to transcriptional repression or activation, depending
on the site of modification. Methylation of H3 at lysine resi-
due 4 (H3K4) is associated with transcriptional activation,
while methylation of H3K9, H3K27, and H4K20 is associ-
ated with transcriptional repression (reviewed in [242]).
Histone methylation marks (including H3K9 dimethylation
(H3K9me2), H3K9 trimethylation (H3K9me3) as well as
H3K27 trimethylation (H3K27me3)) have been shown to
be associated with HIV-1 transcriptional silencing in differ-
ent postintegration latency models [66,68,207,243,244].
The histone methyltransferases (HMTs) Suv39H1
[243], which is primarily involved in H3K9me3, and G9a
[244] which is responsible for H3K9me2, have been
demonstrated to play a role in HIV-1 transcriptional si-
lencing (Figure 2). Indeed, Benkirane’s group [243] has
shown that Suv39H1, HP1gamma (heterochromatinprotein 1) and H3K9me3 mediate HIV-1 repression in
different cellular models including PBMCs from HIV+
patients. Moreover, Rohr’s laboratory has previously
reported a similar mechanism in in vitro HIV-1-infected
microglial cells, where Suv39H1 is recruited to the HIV-
1 promoter via the transcriptional corepressor CTIP2
leading to a multi-enzymatic complex including HDAC1,
HDAC2 and HP1 [207,211]. In this context, a study has
very recently reported increased CTIP2, HP1, MeCP2
and HDAC1 levels in postmortem brain tissue from HIV
+ latent cases, most probably due to posttransciptional
mechanisms [245]. In addition, G9a-mediated H3K9me2
can also recruit HP1 and therefore participate in the
maintenance of HIV-1 silencing [244]. Results from Ding
et al. suggest that the G9a-like-protein (GLP) may also
play a significant role in the maintenance of HIV-1 la-
tency by catalyzing H3K9me2 in new clonal cell lines
where the provirus is integrated in active gene regions
and presented an hypomethylation status [246]. To-
gether, their data suggest that histone methyltransferase
inhibitors (HMTIs) could represent promising thera-
peutic drugs in strategies aimed at purging the HIV-1 la-
tent reservoirs.
Two specific HMTIs have been described so far:
chaetocin and BIX-01294. Chaetocin, a fungal mycotoxin
from Chaetomium minutum [247], acts as a specific
inhibitor of Suv39H1 in a S-adenosylmethionine (SAM)-
competitive manner [248]. Chaetocin belongs to 3-6-epi-
dithio-diketopiperazines, which have been previously
reported to have biologic effects including immunosup-
pressive [249], anti-inflammatory [250] and/or antiviral
[251] activities. BIX-01294, a diazepin-quinazolin-amine
derivative, functions as a specific inhibitor of G9a [252]
in an uncompetitive manner with SAM by binding the
G9a SET catalytic domain [252,253]. Recently, Van Lint’s
group demonstrated that the HMTI chaetocin induces
HIV-1 recovery in 50% of the CD8+ depleted PBMCs
cultures tested and in 86% of the resting CD4+ T-cell
cultures from HIV-1+ cART-treated patients with un-
detectable viral load [98]. They next confirmed the high
reactivation potential of HMTIs using BIX-01294, which
induced HIV-1 recovery in 80% of the patient resting
memory CD4+ T-cell cultures tested [98]. This study
and several other recent studies demonstrate that the
specific HMTIs chaetocin and BIX-01294 reactivate la-
tent HIV-1 with minimal effects in different latently
infected cellular models compared to the effects
observed in patient cells [66,68,98,244]. Moreover, the
Van Lint’s group has shown that the combinations
chaetocin + prostratin and chaetocin + SAHA causes, in
most cases, a higher HIV-1 reactivation than these com-
pounds used alone [98], in agreement with the fact that
a combination of two different HIV-1 inducers can act
on different mechanisms of latency. They also observed
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smaller group of patient cell cultures. In conclusion, the
Van Lint’s group showed for the first time that HMTIs,
alone or in combination with HIV-1 inducers, cause HIV-
1 recovery in resting memory CD4+ T cells from cART-
treated patients [98]. Although chaetocin and BIX-01294
cannot be safely administered to humans, the latter results
constitute a proof-of-concept for the use of HMTIs in
strategies aimed at reducing the pool of HIV-1 latent res-
ervoirs. Since HMTIs also represent promising com-
pounds in anti-cancer therapies [254-256], other safer
HMTIs should be synthesized soon and evaluated for their
reactivation potential in cells from HIV-1+ cART-treated
individuals.
Suv39H1-mediated trimethylation requires previous de-
methylation of H3K4 by Lysine-specific demethylase 1
(LSD-1/KDM1) [257]. The Rohr’s and Van lint’s groups
have recently postulated that this histone demethylase
may be part of the multienzymatic complex recruited by
CTIP2 to the HIV-1 promoter [258]. They have reported
that LSD1 functionally cooperates with CTIP2 in a syner-
gistic manner to repress both viral replication and tran-
scription in microglial cells, the main HIV-1 targets in the
central nervous system [258]. They also demonstrated that
CTIP2 and LSD1 interact by coimmunoprecipitation ex-
periments and colocalize in cells with the HIV-1 Tat pro-
tein within heterochromatic nuclear structures by
confocal microscopy experiments [258]. Altogether, their
results support the idea that LSD1 and CTIP2 cooperate
to repress the HIV-1 promoter. Recruitment of LSD1 at
the HIV-1 proximal promoter is associated with induction
of both H3K4 and H3K9 trimethylation in the U1 mono-
cytic/macrophage cell line. Mechanisms underlying LSD-
1-mediated increase in H3K4 trimethylation might rely
rather on the ability of LSD1 to recruit hSET1 and
WDR5, two members of the hCOMPASS complex, at the
promoter than on its own enzymatic demethylase activity
[258]. These data suggest that the transcriptional repres-
sor LSD1 constitute a potential target (at least in infected
cells of the monocytic/macrophages lineage) to induce
HIV-1 latency with histone demethylase inhibitors. In
contrast, in latently infected T cells, the LSD1/KDM1/
CoREST complex, normally known as a transcriptional
suppressor, was shown to act as an activator of HIV-1
transcription through specific demethylation of K51 in Tat
[259]. The two studies thus observed opposite effect of
LSD1 in microglial cells versus in T cells. This could be
due to cell type-specific differences that should be further
investigated.
In addition to H3K9 methylation, the Karn’s laboratory
has elegantly demonstrated that the HMT enhancer of
Zeste 2 (EZH2, a HMT that is part of the Polycomb Re-
pressive Complex 2, called PRC2), the enzyme respon-
sible for H3K27me3, is present at high levels at the LTRof silenced HIV-1 proviruses and was rapidly displaced
following proviral reactivation in T cells (Figure 2 [66]).
This correlates with H3K27 trimethylation of the HIV-1
promoter in latency conditions, inducing a repressive
chromatin structure, and with a decreased H3K27me3
level in activated conditions [66]. Recently, the group of
Tyagi has reported that CBF-1 (C-promoter binding
factor-1) is responsible for the recruitment of EZH2 and
other chromatin-modifying enzymes of the Polycomb
complex to the HIV-1 promoter [27]. The complex in-
cluding EZH2 is very important because it can serve as a
binding platform for multiple histone- and DNA-
modifying enzymes [260,261]. Treatment of cells with
the broad spectrum HMTI DZNep has shown HIV-1 re-
activation of silenced proviruses and a significant inhib-
ition of EZH2 activity in a primary T-cell latency model
[66]. However, DZNep is not a specific inhibitor of
EZH2 but possesses only a greater inhibitory potency for
EZH2 than for other HMTs. Indeed, DZNep is an inhibi-
tor of S-adenosyl-L-homocysteine (SAH) hydrolase and
thus inhibits indirectly EZH2 through effects on intra-
cellular SAH concentrations and promotes degradation
of the PRC2 complex [262]. EZH2 is also implicated in
tumorigenesis and correlates with poor prognosis in sev-
eral tumor types [263-266]. In this context, a recent study
identified specific inhibitors of EZH2 methyltransferase
activity by a high throughput biochemical screen [267]. In
a linked study, a small molecule of this screen has been
optimized resulting in a highly selective, potent, SAM-
competitive inhibitor of EZH2, named GSK126 [268].
They demonstrated that GSK126 decreases global
H3K27me3 levels and reactivates silenced PRC2 target
genes in lymphoma. GSK126 has been also evaluated in
mice where it was well tolerated and similar results were
observed in cell culture [268]. Therefore, it would be in-
teresting to evaluate the GSK126 molecule for its reactiva-
tion potential on latent HIV-1 in infected patient cell
cultures.
DNA methylation
In mammalian cells, DNA methylation occurs as 5-methyl
cytosine predominantly in the context of CpG dinucleo-
tides and is achieved by the specific recruitment of DNA
methyltransferases (DNMTs). DNA methylation in tran-
scriptional regulatory regions is generally associated with
gene silencing, either by directly blocking binding of
transcription factors to their recognition sequences or
by indirectly preventing transcription factors from
accessing their target sites through attachment of
methyl-CpG-binding proteins (MeCPs) that “read” DNA-
methylation patterns. These MeCPs recruit HDACs and
HMTs, thereby resulting in formation of a closed repressive
chromatin structure (for review [269]). During latency, the
HIV-1 promoter is hypermethylated at two CpG islands
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strated both in J-Lat cell lines and in the Planelles’s primary
T cell model of HIV-1 latency ([270], Figure 2). In J-Lat
cells, methyl-CpG binding domain protein 2 (MDB2) and
HDAC-2 are recruited to the promoter via the second CpG
island [270]. Treatment with 5-aza-2’deoxycytidine (5-
Aza-CdR, decitabine) decreases cytosine methylation in the
two HIV-1 CpG islands, resulting in loss of MBD2 and
HDAC-2 from CpG island 2 of the viral promoter region
and in partial transcriptional reactivation [270]. The group
of Hirsch compared the CpG dinucleotide methylation pat-
tern of the HIV-1 promoter in aviremic versus viremic
HIV-1-infected individuals by bisulfite sequencing of DNA
from memory resting CD4+ T cells [271]. Analysis of the
CpG methylation profile has shown that the HIV-1 5’LTR
in 6 patients without detectable plasma viremia contain
from 19% to 100% of methylated CpG compared with less
than 0.1% for the control group of viremic patients. These
results indicate that HIV-1 promoters in the long-term
cART-treated aviremic individuals are hypermethylated, in
contrast to non-methylated promoters of viremic patients
[271]. However, more recently, J. Blazkova now in Fauci
and Chun’s laboratory reported novel contrasting results.
Indeed, they examined the methylation status of the first
CpG island by bisulfite sequencing in resting CD4+ T cells
from 11 aviremic patients and did not find significant
5’LTR methylation in any of them [272]. They observed a
median frequency of methylated CpG dinucleotides within
the HIV-1 5’LTR of 2.4% (range 0-10%) [272]. Both groups
used the same technique of DNA methylation analysis
and the same system of controls based on Jurkat clones.
The major sources of differences between both studies
could originate from variability in patients characteristics
and cART treatments. The patients from the Hirsh’s study
with the most heavily methylated 5’LTRs were long-term
infected individuals (infected for 11, 12 and 16 years, with
a median of 10 years of ART). Some of them were treated
by inefficient therapy at the beginning (see Supplementary
Table 3 in [271]). In contrast, the longest treatment period
in the Fauci’s study was 6.6 years with a median of
2.9 years. Another difference between both studies is
the population of analyzed CD4+ T cells: HIV-1 provi-
ruses analyzed in the Hirsh’s study were extracted from
memory CD4+ T cells, while HIV-1 proviruses ana-
lyzed in the Fauci’s paper were obtained from resting
CD4+ T cells. More stringent mechanisms of mainten-
ance of HIV-1 latency, including CpG methylation,
may be needed in the memory CD4+ T cells, which are
more prone to proliferate than the resting CD4+ T
cells. Since DNA methylation may be a late event that
enhances silencing of already-latent viruses rather than
contributing to entry into latency, the time of infection in
each patient may be an important factor contributing to
the differences between both studies. Indeed, substantiallylonger period of selection of latent proviruses in the
memory cell population [271] can result in accumulation
of HIV-1 proviruses with methylated promoters in com-
parison to non-methylated HIV-1 proviruses harbored in
the shorter-term-selected population of resting cells
[272]. Very recently, Palacios et al. have compared the
methylation state of the HIV-1 promoter in PBMCs from
two group of infected patients: 1) long-term nonprogressors
and/or elite controllers (the LTNP/EC group) who maintain
undetectable or low levels of viremia (< 50 or 2000 RNA
copies/ml, respectively) without treatment, and 2) aviremic
patients in whom cART results in undetectable plasma
viremia. Palacios et al. have shown that the 5’LTR of HIV-1
in all aviremic patients exhibited very low or no methyla-
tion at all (range of 0 to 1%) compared with that the LTNP/
EC group, where the percentage of methylated CpGs in the
HIV-1 promoter was higher (median of CpG methylation
of 5.4%). However, it is difficult to compare this latter study
with the two previous ones [271,272] because bisulfite ana-
lysis was performed on total PBMCs (containing other
infected cells such as monocytes in addition to the CD4+ T
cells) instead of memory CD4+ T cells. Palacio et al. have
observed a weak 5’LTR DNA methylation level in the
LTNP/EC group, thereby strengthening the hypothesis that
DNA methylation is an epigenetic mark associated with
certain forms of latency. Evidently further studies will be
necessary to clarify the role of DNA methylation in HIV-1
latency in vivo.
Various anticancer agents including 5-aza-2'deoxycytidine
(5-Aza-CdR), an FDA-approved inhibitor of DNA methyla-
tion used in humans to treat myelodysplastic syndrome
(marketed as Decitabine) [273], were shown to induce
HIV-1 transcription in latently infected cell lines [274] and
in a doxycycline-dependent HIV-rtTA variant [76]. How-
ever the role of DNA methylation in HIV-1 latency is still
controversial, and some laboratories have even reported
that CpG methylation did not correlate with transcriptional
silencing [275]. In addition to the four well-characterized
nucleoside analog methylation inhibitors (i.e. 5-azacytidine
(5-Aza), 5-Aza-CdR, 5-fluoro-2'-deoxycytidine, and zebularine),
there is a growing list of non-nucleoside DNA methylation
inhibitors such as procaine, procainamide, hydralazine and
RG108 [276]. Only 5-Aza and 5-Aza-CdR are currently
FDA-approved and used in cancer therapies. The major
hindrance of their usage in humans is their instability
in vivo and the toxicity secondary to their excessive incorp-
oration into DNA, which causes cell cycle arrest. These
cytosine analogs have also been demonstrated to induce
proteasomal degradation of DNMT1 [277]. Today, no clin-
ical trial with HIV-1-infected patients has been performed
using DNA methylation inhibitors to reduce the pool of la-
tent reservoirs, but it could an interesting approach.
In addition to their DNA methylation inhibitory activ-
ity, 5-Aza and 5-Aza-CdR were reported to exhibit
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aimed at curing HIV-1 infection. Indeed, it was reported
that the primary antiviral mechanism/activity of 5-Aza
(after reduction to 5-Aza-CdR) and of 5-Aza-CdR could
be attributed to their ability to increase the HIV-1 mu-
tation rate through viral DNA incorporation during re-
verse transcription [278]. This results in decreased
HIV-1 replication and infectivity through lethal muta-
genesis. Clouser et al. have shown that a combination
of two clinically approved drugs, decitabine and
gemcitabine (2'-deoxy-2',2'-difluorocytidine, a nucleo-
side analog also presenting ribonucleotide reductase
inhibitory activity), reduced HIV-1 infectivity by 73%
at concentrations that had minimal antiviral activity
when used individually [279]. Recently, the same group
has shown that 5-Aza-CdR in combination with
gemcitabine, a FDA-approved drug, inhibited disease
progression at doses that were not toxic in murine
AIDS model, as detected by histopathology, viral loads,
and spleen weights [280]. Resveratrol (a ribonucleotide
reductase inhibitor) was also shown to inhibit HIV-1
infectivity in combination with 5-Aza-CdR [281].
Combinations of a DNA methylation inhibitor with a
HDACI has been previously used in clinical trials as anti-
cancer treatments. A combination 5-Aza-CdR/VPA has
been tested in latently infected cell lines but failed to syner-
gistically reactivate HIV-1 transcription [270]. However, in
the same experiment, the authors showed that inhibiting
provirus methylation led to an almost complete reactivation
of latent HIV-1 in J-Lat T cells when combined with the
NF-kappaB signaling activator TNFalpha [270]. In another
study, 5-Aza-CdR was also shown to synergize with
prostratin, which triggers reactivation of latent HIV-1 with-
out broad T-cell activation and inhibits de novo virus infec-
tion [144]. Fernandez and Zeichner have shown that
5-Aza-CdR plus TNFalpha activates HIV-1 at least twice as
well as TNFalpha alone in almost all J-Lat cell lines tested
but the J-Lat 10.6 cell line, in which TNFalpha plus 5-Aza
-CdR moderately decreases activation compared to the acti-
vation observed after treatment with TNFalpha alone [282].
Surprisingly, 5-Aza-CdR decreased TNFalpha-induced acti-
vation of HIV-1 gene expression to an even greater extent
in the latently infected cell lines ACH2, J1.1 and U1 than in
the J-Lat 10.6 cell lines [282]. In certain cell lines, the au-
thors also observed that 5-Aza-CdR decreases induction of
viral expression by the HDACI TSA [282]. These differen-
tial responses to epigenetic inducers observed in the various
cell lines may be due, in addition to the direct effect of the
epigenetic drugs on LTR demethylation, to different indir-
ect effects on cellular genes that directly or indirectly in-
hibit HIV-1 transcription. Recently, the Van Lint’s group
has shown that 5-Aza-CdR in combination with the
HDACI SAHA synergistically induces HIV-1 gene expres-
sion in several J-Lat cell lines (Bouchat and Van Lint,unpublished data). The reactivation potential of 5-Aza-CdR
is currently tested in combination with others HIV-1 in-
ducers in ex vivo cultures of resting CD4+ T cells from
cART-treated HIV-infected patients with undetectable viral
load (Bouchat and Van Lint, unpublished data). The use of
DNA methylation inhibitors coupled with a PKC agonist or
with an HDACI could be a further step to purge the latent
reservoirs in cART-treated patients.
The viral protein Tat and associated cofactors
Tat is the viral trans-activator of transcription that
binds the transactivation response RNA element (TAR,
Figure 2) at the 5’-end of all viral transcripts to promote
transcriptional elongation (for a review: [283]). Tat is a
promiscuous viral protein that has been show to associ-
ate to a number of host factors. However, the first com-
prehensive protein-protein interaction network of HIV-1
infected cells showed a remarkably low number of hits
for Tat, which included the well described Cyclin T1 and
CDK9, but excluded several others [284]. The levels of
Tat in an infection are certainly physiologic, may be too
low at the time of harvest to be able to pull down all the
possible interactors. Indeed, several recent studies iden-
tified important Tat cofactors by overexpressing tagged-
Tat alone in cells (see below). Furthermore, careful
inspection of the crude data of Krogan’s work shows the
presence of some already identified factors and the cri-
teria of inclusion for the final network representation
should be analyzed carefully. For example, the nucleo-
some assembly factor 1-like 1 (NAP1L1), which was pre-
viously shown to functionally interact with Tat, can be
found also in Krogan’s pulldowns associated to Tat and
other viral proteins and therefore exclude for specificity
reasons [285,286] To note that NAP1L1 was also de-
scribed as functional interactor of the Rev protein [287].
In the following chapters, we will focus on Tat and its
partners according to the latest information available.
Tat and P-TEFb
The HIV-1 promoter is a widely used model for mam-
malian RNAPII elongation control and has provided sev-
eral insights in the general mechanism of cellular
transcription. In the absence of the viral transactivator
Tat, basal transcription from the long terminal repeat
(LTR) leads to RNAPII pausing after synthesis of a short
RNA that includes TAR. The negative elongation factors
NELF and DSIF induce RNAPII pausing on the pro-
moter but few molecular details of this process are
known (reviewed in [288]). Kiernan and collaborators re-
cently proposed that also RNA contributes to pausing
[289]. The recruitment of the Microprocessor complex,
Rrp6 exoribonuclease and of the termination factors
Setx and Xrn2 induces the cleavage of the short TAR
hairpin leading to premature termination by an RNAi
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on a subset of cellular genes reinforcing the notion that
post-initiation events are a hallmark of cellular gene
regulation. Indeed, genome-wide mapping studies re-
vealed promoter-proximal pausing of RNAPII on a large
proportion of human genes (ENCODE Transcriptome
Project, 2009; [290-292]).
Tat, together with P-TEFb, binds the stem loop within
TAR, allowing cdk9 to phosphorylate the RNAPII
carboxyterminal domain (CTD) and the negative tran-
scription elongation factors NELF and DSIF, licensing
RNAPII for productive elongation (Reviewed in
[293,294]). Tat recruits Cyclin T1/cdk9 either from the in-
active complex containing the 7SK snRNA, HEXIM1 (or
his homologue HEXIM2) (Figure 2), the La-related protein
7 (LARP7), and the 7SK-specific methyl-phosphate-cap-
ping enzyme (MePCE) or from the Cyclin T1/cdk9 com-
plex containing the bromodomain-containing protein 4
(BRD4) active on cellular genes. However, other Cyclin
T1/CDK9-associated protein complexes that negatively
modulate Tat activity have been recently identified
[295,296]. Frankel’s group reported the unexpected find-
ings that Tat assembles into a complex with P-TEFb in its
inactive 7SK snRNP form and that this complex is
recruited to the HIV-1 promoter before transcription initi-
ation in a TAR-independent manner. Once transcription
begins, the nascent TAR hairpin is synthesized and is re-
quired to displace the inhibitory 7SK snRNP complex and
activate the P-TEFb kinase, which occurs when Tat and
CycT1 bind to TAR [297].
Recent advances in live cell imaging allowed direct
measurements of RNA biogenesis from the HIV-1 pro-
moter exceeding 50 kb min-1 [298]. The studies of
Marcello and collaborators demonstrate that Tat-
mediated HIV-1 transcription is highly efficient and able
to produce a large amount of pre-mRNA in a short time
[299]. Tat is such an effective elongation factor possibly
because it is able to recruit the “super elongation com-
plex” (SEC) in addition to P-TEFb. Independent work by
the Benkirane and Zhou laboratories using an affinity-
purification strategy led to the identification of ELL1
and its homolog ELL2, AFF1 and its homolog AFF4,
ENL, AF9 and components of the polymerase-associated
factor complex (PAFc) as SEC components of the Tat/P-
TEFb complex [300,301]. ELL1 and ELL2 are well-
characterized transcription elongation factors that
stimulate the processivity of RNAPII and act in concert
with P-TEFb. The SEC was also independently identified
associated to the mixed-lineage leukemia (MLL) protein
to promote expression of MLL-dependent genes [302].
However, SEC components ENL/AF9/AFF4 interacting
with PAFc/RNAPII are able to promote elongation of
genes independently of Tat/MLL and were shown to in-
crease HIV-1 basal transcription [303]. Control of SECby ubiquitination and its reactivation by prostratrin and
HMBA (Hexamethylene bisacetamide) represents a
novel avenue for developing strategies to control HIV-1
transcription.
HMBA, a hybrid bipolar compound, is a clinically tol-
erable agent, which was first developed as an anticancer
drug [304,305]. HMBA was previously shown to reacti-
vate viral production in chronically infected cell lines
[306,307]. HMBA activated transiently the PI3K/Akt
pathway, which leads to the phosphorylation of HEXIM1
and the subsequent release of P-TEFb from its transcrip-
tionally inactive complex with HEXIM1 and 7SK snRNA
[308]. Moreover, HMBA triggers Cdk9 recruitment to
the HIV-1 5'LTR via an unexpected interaction with the
transcription factor Sp1, resulting in stimulation of tran-
scription elongation and viral production [309]. HMBA
was shown to induce HIV-1 gene expression in the la-
tently infected T-lymphoid (ACH2, Jurkat cells) and U1
monocytic cell lines and in resting CD4+ T cells isolated
from PBMCs which were infected in vitro with HIV-1LAI
[308]. Moreover, Klichko et al. have reported that treat-
ment with HMBA downregulates expression of CD4 in
PBMCs, but does not alter expression of the HIV-1 co-
receptors CXCR4 and CCR5 [310]. However, unlike
mitogen activation, HMBA did not increase cell suscep-
tibility to HIV-1 infection or the expression of cell sur-
face markers of activation [310].
In order to affect the P-TEFb equilibrium, five inde-
pendent studies have very recently reported that JQ1 (an
inhibitor of BET bromodomain BRD4 [311]) is able to
reactivate latent HIV-1 [312-316]. The most recent study
has also shown that 3 other BRD4 inhibitors (I-Bet, I-
Bet151 and MS417) reactivate HIV from latency [316].
The bromodomain containing protein BRD4 and its in-
hibition of Tat-transactivation is a major impediment to
latency reactivation [313]. BRD4 competitively blocks
the Tat-SEC interaction on the HIV-1 promoter [313].
The BET bromodomain inhibitor JQ1 dissociates BRD4
from the HIV-1 promoter to allow Tat recruitment of
SEC to stimulate HIV-1 elongation. Others studies have
shown that JQ1 transiently increases levels of free P-
TEFb and BRD4/P-TEFb and SEC/P-TEFb complexes in
cells [312]. Indeed, although primarily thought of as an
epigenetic modifier, JQ1 also affects the P-TEFb equilib-
rium directly by removing P-TEFb from the 7SK snRNP
or by an indirect effect via stress, as the structure of
chromatin changes upon release of BRD4. The BRD4
loss enhances HIV-1 gene expression by increasing Tat/
P-TEFb association and RNAPII transcriptional elong-
ation [315]. Importantly, JQ1 was shown to reactivate la-
tent HIV-1 in several cellular models for postintegration
latency: in T lymphoid latently infected cell lines
[312-315], in the latently infected U1 monocytic cell line
[315], in a primary T-cell model of HIV latency [316],
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Montano’s group has reported HIV-1 recovery in one of
the three resting CD4+ T cell ex vivo cultures prepared
from HIV-1-infected cART-treated patients [314]. The
Brass’s group has tested the reactivation potential of JQ1 in
ex vivo cultures of CD8+ depleted PBMCs isolated from 19
cART-treated patients with undetectable viral load and has
shown that JQ1 alone does not induce HIV-1 recovery but
potentiates the actions of several known HIV-1 inducers
(PHA, PMA, TNFalpha, prostratin) [315]. This could be
explained by the very low level of Cyclin T1 in resting T
cells. Li et al. also have reported that JQ1 potentiates HIV-1
reactivation by prostratin and PHA in the J-Lat A2 latent
cell line [313]. In addition to BRD4, the study of Ott and
Verdin has also identified BRD2 as a new Tat-independent
suppressor of HIV-1 transcription in latently infected cells
and underscored the therapeutic potential of BET inhibitors
in the reversal of HIV latency [316].
Tat itself can be a target for therapeutic intervention
at various levels [317,318]. Recently, the first crystal
structure for Tat bound to P-TEFb was reported [319].
This structure resolved at 2.1 angstroms, reveals intim-
ate contacts between Tat and the T loop of cdk9 and
marked interactions of Tat and with cyclin T1. This
structure could lead to the rational design of a new class
of HIV-1 inhibitors.
The “tat code”
The interaction promiscuity of Tat cannot be explained by
a single peptide. Similar to the “histone code” [320] that
has been proposed to explain how histones interact with
several chromatin associated factors, which can activate or
repress transcription, Tat can be posttranslationally modi-
fied at various residues, thereby creating a variety of
isoforms with specific functions, the “Tat code”. Phosphor-
ylation of Tat was the first modification identified, but
there has been little follow up on is role in Tat activity. Ly-
sine acetylation has been described at Lys28 allowing high-
affinity binding to P-TEFb [321,322]. Lys28 acetylation is
reversed by HDAC6 [323]. Acetylation at Lys50/51 leads to
the dissociation of Tat from TAR and promotes the associ-
ation of the bromodomain-containing p300/CBP associ-
ated factor (PCAF) acetyltransferase [321,322,324-327].
Lys50 acetylation generates an interaction surface also for
the SWI-SNF chromatin-remodeling complex [328].
Deacetylation of Tat is mediated by SIRT1 and possibly
controls a late step in Tat transcriptional activity, allowing
the recycling of the deacetylated protein for next rounds of
transcription [329]. Lys51 is also methylated by the
monomethyl-transferase Set7/9 and demethylated by the
action of LSD1 [259,330]. Interestingly, both activities are
required for Tat function, possibly controlling different
steps of process. To this end, the dwell time calculated by
fluorescence recovery after photobleaching (FRAP) of thevarious components present at the HIV-1 transcription
site showed that Tat and Cdk9 behave similarly while
RNAPII remains on the gene for a longer time required
to reach the end of the gene [331,332]. These data sup-
port the idea that Tat and P-TEFb remain associated in
the elongating complex, rather than Tat alone being
transferred to the elongating polymerase, but that the
complex dissociates from RNAPII before termination of
transcription. Finally, polyubiquitination of Lys71 medi-
ated by the proto-oncoprotein Hdm2 does not induce
proteasome-dependent degradation but has an activat-
ing effect on Tat [333]. Tat interacts also with the 19S
PAAF1 component of the proteasome to increase tran-
scription in a non-proteolytic mode [334]. However, the
role of Lys71 polyubiquitination in this pathway of Tat
activation has not been established yet. Since posttrans-
lational modifications are critical for Tat activity, they
represent targets for antiviral therapy. For example, the
structure of the Tat/PCAF interaction is being explored
for the development of antiviral compounds [335-337].
Recruitment of the SWI /SNF chromatin-remodeling
complex to the HIV-1 promoter
Integrated HIV-1 is embedded into host chromatin and
shows a characteristic histone signature with the position-
ing of nuc-1. Remodeling of histones is required for tran-
scription (see above). This could be achieved by specific
posttranslational modification of histone tails, such as
acetylation and methylation, and by remodeling com-
plexes that require ATP to function. The SWI/SNF family
complexes contain the Brahma (BRM) or homologue
BRG1 ATPases together with several other components.
Two distinct SWI/SNF complexes have been described:
BAF and PBAF. The defining subunit of the BAF complex
is BAF250a/ARID1a, and those of the PBAF complex are
BAF180, BAF200, and BRD7. SWI/SNF complexes partici-
pate in the activation of HIV-1 transcription. Kashanchi
and collaborators showed that Tat activates HIV-1 tran-
scription in the G1/S phase of the cell cycle [338]. Acety-
lated Tat binds BRG1 and both are recruited to the 5’ LTR.
BRG1 knockdown in latently infected cell lines, such as U1
and ACH2 stimulated with TNFalpha, result in a significant
decrease of viral gene expression. Consistently, Verdin and
collaborators have shown that knockdown of the core
SWI/SNF components integrase interactor 1 (INI-1/SNF5)
and BRG-1 suppresses Tat-mediated transactivation and
that Tat BRG1 interaction requires Lys50/51 acetylation
[328]. They also demonstrated that BRG1 and INI1 co-
operate with the p300 coactivator and acetyltransferase to
synergistically activate the HIV-1 LTR. The Emiliani’s
laboratory demonstrated that BRM is required for proper
Tat-mediated activation of the HIV-1 LTR [339]. They
showed that Tat fails to transactivate the 2037 integrated
LTR if BRM is depleted by siRNA in HeLa cells.
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with BRM. More recently, it has been reported that estab-
lishment and maintenance of HIV-1 latency requires the
BAF complex, which helps positioning of the repressive
nucleosome-1 immediately downstream of the HIV-1 tran-
scriptional start site [340]. Depletion of BAF-specific sub-
units results in de-repression of HIV-1 latency concomitant
with the loss of nuc-1. Upon transcriptional activation, BAF
is lost from the HIV-1 promoter, while the PBAF complex
is selectively recruited by acetylated Tat to facilitate LTR
transcription. Thus, BAF and PBAF, recruited during differ-
ent stages of the HIV-1 life cycle, display opposing func-
tions on the HIV-1 promoter.
The involvement of SWI/SNF in HIV-1 is more com-
plex since it may involve other mechanisms beyond
transcription. The core SWI/SNF component INI1/SNF5
was originally identified as an interactor of HIV-1
integrase [341]. It has been proposed that by interacting
with IN, INI/SNF5 interferes with early steps of HIV-1
infection [342]. More recently, it has been shown that
HIV-1 integration requires nucleosome remodeling at
the integration site and that this activity is mediated by
the interaction of INI1/SNF5 with the viral integrase
[119]. Finally, an intriguing observation by the Trono’s
laboratory, which has not been investigated further, indi-
cated that incoming HIV-1 pre-integration complexes
trigger the nuclear export of INI1/SNF5 and of the nu-
clear body component PML (TRIM19) [343]. The HIV-1
genome appears to associate with these proteins before
nuclear export. PML is sequestered in the nucleus in the
presence of arsenic while the INI1/pre-integration com-
plex interaction is disrupted and the efficiency of HIV-1
infection is increased [343]. These data suggest a repres-
sive role for INI-1/hSNF5 in HIV-1 transcription.
Posttranscriptional mechanisms of HIV-1 latency
Considerable attention has focused on the role of chro-
matin and transcription (co)factors in the control of
HIV-1 latency. However, latently infected cells are also
maintained in a suboptimal cellular environment for
HIV-1 expression by mechanisms operating at the post-
transcriptional level either by inhibiting nuclear viral
RNA export or by inhibiting HIV-1 translation.
The generation of infectious retroviral progeny re-
quires the synthesis and export to the cytoplasm of three
species of RNA: (i) spliced subgenomic mRNAs for pro-
tein translation, (ii) partially spliced RNAs that function
as the mRNA for the viral proteins Gag-Pol and Env and
(iii) genomic unspliced full-length viral RNA. The viral
protein Rev promotes the export of RNAs from the nu-
cleus through the association to an RNA element called
the Rev response element (RRE) that is present in par-
tially spliced and genomic RNAs. Nuclear export occurs
upon association of Rev with the nuclear export factorExportin 1 (Crm-1) and translocation of the Rev/RNA
complex to the cytoplasm where it is either translated or
packaged into virions (for a review:[344]). Siliciano and
colleagues have reported that resting CD4+ T cells from
HIV-1-infected individuals on cART retain both Tat and
Rev transcripts in their nuclei [345]. This finding stands in
sharp contrast to the effective export of these multiply
spliced viral transcripts in activated CD4+ T cells. The de-
fect in viral RNA export could be rescued by ectopic ex-
pression of the RNA binding protein PTB (polypyrimidine
tract binding protein). PTB, the PTB-associated factor PSF
and Matrin 3 have all been identified as HIV-1 RNA bind-
ing factors [346-349]. Although it has been proposed that
HIV-1 (partially) spliced RRE-containing HIV-1 RNAs are
committed to Matrin3/Rev mediated export by PSF, their
role in HIV-1 latency remains to be determined [349]. Of
note, however, that Rev expression alone is able to in-
crease HIV-1 expression in resting CD4+ T lymphocytes,
indicating that defects in viral RNA export could result
also from insufficient levels of Rev [350].
Critical to the study of HIV-1 latency is the choice of
the cellular model. It was recently reported that the dir-
ect infection of resting CD4+ T cells by spinoculation re-
sults in the generation of a population of cells carrying
integrated proviruses, that are capable of producing low
levels of Gag but are unable to spread the infection
[351]. The defect appeared at the level of Env produc-
tion and could be reversed by T cell stimulation. This
observation opens yet a novel scenario on the post-
transcriptional regulation of HIV-1 latency.
Micro RNAs (miRNA) are short non-coding single-
stranded RNAs that mediate post-transcriptional gene silen-
cing (PTGS). Following RNAPII transcription, pri-miRNA
transcripts are processed in the nucleus by Microprocessor,
an enzymatic complex containing Drosha. The resulting
pre-miRNAs are exported to the cytoplasm and cleaved by
Dicer into the mature form, which is incorporated into the
RNA-induced silencing complex (RISC). The miRNA-RISC
then typically binds to the 3’-untranslated region (3’UTR) of
a target mRNA, leading to translational repression. Several
changes in the miRNA profile of various cohorts of HIV-1
infected patients have been observed [352-354]. However,
these studies are more indicative of the cellular environment
of a particular patient, or cohort of patients, rather than the
direct effect of viral infection given the low percentage of
HIV-1 infected cells in vivo. Knockdown of Dicer or Drosha
increases HIV-1 replication [355,356], but this phenotype
could depend on complex effects on non-miRNA and
miRNA pathways that influence the processing of cellular
and viral miRNAs. Direct assessment of miRNA profiles
changes induced by HIV-1 infection has been approached
directly in linfoblastoid cell lines and/or cultured PBMCs
infected ex vivo [352,355,357-359]. Both up-regulation and
down-regulation of cellular miRNAs have been observed
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Vpr, function as RNA silencing suppressors (RSS) being
able to modulate miRNA expression levels in infected cells
[360-362] miRNAs could inhibit HIV-1 gene expression
by decreasing the levels of essential cellular co-factors and
are involved in the susceptibility to HIV-1 infection of dif-
ferent cell types like monocytes compared to macrophages
for example [363]. The first essential cofactors of viral
transcription that have been shown to be modulated by
miRNAs are the PCAF acetyltransferase [355] and Cyclin
T1 [364-366]. PCAF is regulated by miR175p and miR20a
in resting T cells, while Cyclin T1 is regulated principally
by miR27b [365,366]. Cyclin T1 expression increases also
during differentiation of monocytes to macrophages due
the down modulation of miR198 that targets the 3’UTR
[364]. In resting CD4+ T cells instead, miRNAs may also
participate in repressing HIV-1 gene expression by directly
targeting HIV-1 mRNAs. Five cellular miRNAs (miR-28,
miR-125b, miR-150, miR-223, and miR-382) recognize the
3’-end of HIV-1 mRNAs and are upregulated in resting,
but not activated, CD4+ T cells [350]. Interestingly, rescue
of HIV-1 from latently infected cells could be achieved by a
combination of complementary antisense miRNAs opening
the way to a novel therapeutic strategy to rescue latent
HIV-1. Two independent groups showed that HIV-1 nef
gene contains a miR-29a targeted site that interferes with
HIV-1 replication [356,367]. Finally, several HIV-1 derived
miRNAs (called virus-derived vmiRNAs) have also been
obtained by in silico analysis, deep sequencing of infected
cells or miRNA expression profiling [358,359,368]. These
include TAR-derived miRNA-TAR5p/3p [369,370] and the
nef-derived miR-N367 [371]. TAR-derived miRNA may
have an anti-apoptotic effect targeting apoptotic genes
[372] or may target directly HIV-1 transcription as it has
been recently proposed [289]. A summary of the principal
miRNAs affecting HIV-1 is shown in Figure 3.
Therapeutic strategies
Despite current effective and life-prolonging cART, a
small population of latently infected cells persists in the
human body. These HIV-1 reservoirs are insensitive to
cART and able to escape from the host immune response
[1,3]. These are therefore a permanent source for virus re-
activation and could be responsible for the rebound of
plasma viral load observed after cART interruption [1,3].
Therefore, cART treatment requires lifelong adherence,
leading to several long-term side effects and a life expect-
ancy lower than that of uninfected individuals. Moreover,
several problems, such as the cost, the access for every-
body, the stigma, the possibility of resistance with non-
adherence, as well as the fact that intensification of cART
is unlikely to lead to eradication, contribute to the neces-
sity of finding a cure. Several therapeutic approaches
aiming at achieving either a sterilizing cure (elimination ofHIV-1 from the human body) or a functional cure (long-
term control of HIV-1 replication and disease progression
in the absence of cART) have been proposed [1,14]. Such
strategies aimed at eliminating the HIV-1 reservoir have
been extensively reviewed in [8,373]. In this review, we
will essentially focus on strategies to induce the reactiva-
tion of HIV-1 production from latently infected cells and
the purge of latent reservoirs.
A sterilizing cure
Strategies for sterilizing cure include hematopoietic stem
cell transplantation and gene therapy. The former is cer-
tainly not a feasible approach for treatment worldwide
but it has provided the first evidence of virus eradication
from an infected patient. The latter aims at rendering
the target cells refractory to infection.
The “Berlin patient”
A breakthrough in HIV-1 research is the first case of a pos-
sible sterilizing cure, “the Berlin patient”. This HIV-1+ pa-
tient was treated for acute myeloid leukemia with multiple
rounds of chemotherapy and hematopoietic stem cell
transplantations from a donor with genetic HIV-1 resist-
ance, a CCR5delta32 homozygous [374]. It is well
established that homozygosity for a naturally occuring 32-
bp deletion in the chemokine receptor CCR5, the major
coreceptor for HIV-1 [375], provides resistance against
HIV-1 acquisition [375-382]. The patient stopped cART
the day prior to transplant and over 5 years later has not
had a rebound in viremia or other indications of viral repli-
cation [383]. However, after this intervention, in vitro stud-
ies demonstrated that the donor-derived cells were
susceptible to infection by X4 virus, but X4 variants have
not emerged in vivo [384]. This cleverly designed strategy
out of fortunate circumstances led to a patient who
remained without viral rebound long after transplantation
and discontinuation of antiretroviral therapy. This case has
renewed hope for gene therapy in order to specifically
eliminate or reduce the expression of HIV-1 coreceptor
CCR5. More recently, a recent report has shown that two
patients under cART with relapsed Hodgkin’s lymphoma
who received a CCR5 −/+ haemopoetic stem-cell trans-
plant, had undetectable proviral DNA and replication-
competent HIV 8–17 several months after transplantation
(Henrich et al. XIX International AIDS Conference,
Washington DC, USA, 22–27 July 2012).
Gene therapy
Gene therapy has been first proposed as a treatment for
HIV-1 infection in 1988 by David Baltimore with the term
“intracellular immunization” [385]. Several approaches of
gene therapy have been proposed in the past. Recently,
RNA based strategies (ribozymes, antisense RNA, small-
interfering RNA) or protein-based strategies such as zinc-
Figure 3 Modulation of HIV-1 replication by miRNA. HIV-1 impacts the cellular miRNA pathways in several ways. The figure shows a
schematic representation of the HIV-1 provirus with the indicated viral genes and LTRs, including the transcription start site in the 3’LTR. PCAF
and Cyclin T1, which are both essential cofactors for viral transcription, are targeted by the indicated miRNAs in resting T cells and monocytes. A
cluster of miRNAs is targeted directly towards the 5'end of the HIV-1 genome and their inhibition rescues infectious virus from resting T cells.
Finally two sets of miRNA that are derived from the HIV-1 genome are shown. Their location within the LTR (TAR and nef) is duplicated (arrows).
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[386,387]). In brief, hematopoetic cells from patients were
either transduced ex vivo with a retroviral vector carrying
a gene for a ribozyme targeting viral RNA encoding the
viral proteins Tat and Vpr [388] or transfected with a vec-
tor delivering a ribozyme targeting the CCR5 co-receptor,
a short-interfering RNA targeting expression of the HIV-1
proteins Tat and Rev, and a RNA decoy to Tat [384]. The
hematopoetic cells or CD4+ T cells can be also treated
with a zinc-finger nuclease that is designed to specifically
eliminate or reduce expression of the HIV-1 coreceptors
CCR5 or CXCR4 (reviewed in [8]). The zinc-finger nucle-
ase can be delivered by adenoviral or retroviral vectors or
by nucleofection. These genetically modified cells were
then transfused back into the autologous donors. Recently
published clinical trials of gene therapy in HIV-1-infected
patients are summarized in [8], Table 1.
A functional cure
A functional cure aims at the long-term control of virus
infection without the drawbacks of cART [389]. Struc-
tured activation of HIV-1 gene expression in latently
infected cells together with an intensive antiviral regi-
men is proposed as an adjuvant therapy aimed at de-
creasing the pool of latent reservoirs. This could be
combined with immune-based strategies aimed at en-
hancing the clearance of latently infected cells which
have been induced to express HIV antigens.
Elite controllers and VISCONTI patients
Several examples of “natural” functional cure exist. Indeed,
a group of rare HIV-1-infected patients spontaneouslycontrol HIV-1 replication in absence of cART for
prolonged periods of time. These patients called “elite
controllers” carry a specific HLA polymorphism and show
an effective cytolytic CD8+ T-cell response and an en-
hanced activity of myeloid dendritic cells [390,391]. This
group represents an imperfect model for a functional cure
because their status is linked to a precise genetic back-
ground that cannot be reproduced therapeutically and also
because they still show disease progression [390]. How-
ever, the study of genetics, viral and immune characteris-
tics of elite controllers can teach us a lot about the criteria
to be taken into account to achieve a transposable func-
tional cure in naïve or chronic HIV-1 infected patients. In
this context, several studies have shown that the reservoir
of elite controllers is significantly smaller with low concen-
tration of HIV-1 DNA in different subsets of blood cells
and in tissues (reviewed in [390,391]). The reservoirs of
HIV-1 establish early in the infection. Consequently, early
treatment may be a potential strategy to reduce or even
control the reservoir and to allow preserving immune re-
sponse. In addition, rare HIV-1-infected patients acquire a
controller status after prolonged cART initiated in the
acute phase [392,393] or, even more rarely, in the chronic
phase [394,395]. Treatment initiation during primary
HIV-1 infection rather than during chronic HIV-1 infec-
tion may: i) further reduce residual viral replication [396],
ii) limit viral diversity [397] and viral reservoirs [398], iii)
preserve innate immunity and T/B cell functions
[399-401], and iv) accelerate immune restoration [402].
Moreover, studies also show that CD4+ T cell counts are
higher and that viral rebound occurs later (and at a lower
level) after the discontinuation of treatment that began
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began during chronic HIV-1 infection [403,404]. In this con-
text, a cohort, called VISCONTI (for Viro-Immunological
Sustained Control after Treatment Interruption), is ongoing
where patients have been treated with prolonged therapy
that was initiated in acute HIV-1 infection and maintain
both undetectable plasma viremia and low cell-associated
DNA levels despite cART interruption for several years
[405]. These individuals are called post-treatment controllers
(PTCs). Importantly, a recent and elegant study from the
same group has characterized a group of 14 PTCs [406].
These authors found that most PTCs were readily distin-
guishable from spontaneous HIV controllers in many re-
spects (severe primary infection, unfavorable HLA
genotypes, low CD8+ T cell activation status). They have
highlighted that the control of viremia following treatment
interruption was associated with very low HIV-1 blood res-
ervoirs in the PTCs. Interestingly, five PTCs experienced a
progressive decline in their viral reservoir after treatment
interruption, which is one of the goals in the search for an
HIV cure [406]. Akey additional element might be a low
reservoir distribution in cell subsets with long lifespan as
naïve and central-memory T cells. They showed that the
cell subsets of all the PTCs analyzed ex vivo carried very
low levels of HIV-1 DNA [406]. These results argue in
favor of early cART initiation and open up new therapeutic
perspectives for HIV-1-infected patients. However, argu-
ments against cART initiation during primary HIV-1 infec-
tion include the potential for long-term toxicity, the
development of resistant viruses and the cost. A low reser-
voir and a boosted immune response seem to be the two
requisite criteria to allow a control of HIV-1 by the host
immune system.
Reactivation of latent reservoirs of HIV-1
Early but unsuccessful attempts at purging the latent pool
of infected cells were performed using IL-2 and other
mitogenic stimuli that mimicked T cell activation
(reviewed in [3]). Initial attempts to reduce the frequency
of latently infected CD4+ resting T cells in patients on
cART have often involved immune activation therapy ap-
proaches. These studies were based on the assumption
that activation of the latent viral reservoir would result in
rapid cell death due to HIV-induced cytopathic effects
and that the infections virus released by these activated
cells would be contained by the administration of cART.
The rational for this is that eradication of latent reservoirs
might be feasible through global cellular activation (by
using for example IL-2, alone or in combination with an
anti-CD3 monoclonal antibody (OKT3) [81,145,407]).
While these therapies significantly reduced latently
infected cell numbers, a rebound of plasma viremia still
occurred several weeks after cART treatment interruption.
Moreover, induction of generalized immune activation isnot really desirable in purging strategies because it leads
to severe side effects in patients and produces an abun-
dance of activated target cells for the neo-synthesized vi-
ruses. However, this latter problem may be partially
resolved by intensification of cART during the treatment
period.
There is now interest in the cytokine IL-7 since it is
more effective in reversing latency than IL-2 via the JAK/
STAT5 signaling pathway [145]. Moreover, IL-7 has been
shown to reactivate HIV-1 in primary T cells and seems
well tolerated in HIV-infected patients [83,88]. The admin-
istration of IL-7 in cART-treated patients was associated
with a small increase or “blip” in plasma HIV-1 RNA
[408,409]. To determine whether IL-7 reduces latent HIV-
1 reservoir, a clinical trial, called ERAMUNE01 directed by
C. Katlama (ClinicalTrials.gov NCT01019551) is ongoing
with HIV-1-infected patients receiving IL-7 in combin-
ation with an intensification of cART (Table 1). The out-
comes of this trial could help in the development of new
and important therapies for HIV-1 eradication, even
though some concerns were reported regarding the use of
IL-7. Indeed, IL-7 drives homeostatic proliferation of
memory T cells and may potentially expand not only unin-
fected cells, but also latently infected cells by inducing pro-
liferation of all cells, specifically transitional memory T
cells [12]. IL-7 has recently been shown unable to reduce
the reservoirs size in a model of HIV-1 latency [89] or to
reactivate the latent viral pool in patients receiving a single
dose to increase their CD4+ T cell count [410]. Therefore,
the results of the ERAMUNE01 clinical trial will be of
great interest.
Up-regulating cellular transcription to induce HIV-1
gene expression has been proposed as another strategy
for reducing latent HIV-1 reservoirs. Recent studies have
identified individual compounds that are capable of re-
versing HIV-1 latency without T-cell activation (de-
scribed in section 6). Among those, HDACIs are the
most studied in anti-HIV-1 clinical trials. In 2005, the
Margolis group used VPA, a relatively weak and non-
toxic HDACI, in a small pilot study in which a modest
decline of the latent reservoir size was observed in three
out of four patients [411]. However, latter studies have
failed to demonstrate any benefit from VPA in reducing
the number of latently infected resting CD4+ T cells
[232,412-414]. Most recently, Routy et al. confirmed that
adding VPA to stable cART does not reduce the latent
HIV-1 reservoirs in virally suppressed patients [415].
This latter multicentre randomized clinical study based
on 56 virologically suppressed patients has shown no
significant reduction in the frequency of CD4+ T cells
harboring replication-competent HIV-1 after 16 and
32 weeks of VPA therapy 500 mg twice a day [415]. A
far more potent HDACI, vorinostat (SAHA), has signifi-
cant potency in promoting HIV-1 replication in vitro
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for the treatment of cutaneus T-cell lymphoma and rela-
tively well tolerated in humans. Vorinostat has already en-
tered two clinical trials to evaluate its effect on latent
infection in HIV-infected patients: one directed by S. Lewin
(ClinicalTrials.gov NCT01365065) at the Alfred Hospital,
Melbourne, Australia and the other by D. Margolis
(ClinicalTrials.gov NCT01319383) at the University of
North Carolina, Chapel Hill, USA (Table 1). The first study
currently evaluates the effect of vorinostat at 400 mg per
day for 14 days, with a primary end point of change in cell-
associated unspliced RNA in CD4+ T cells isolated from
both blood and rectal tissue. Results from this study should
be available in the next 1–2 years (reported in [226]). In the
second study published in July 2012, the Margolis’s group
reported that administration to cART-treated patients of a
single clinically tolerable dose of vorinostat disrupts HIV-1
latency in blood resting CD4+ T cells. Briefly, these authors
first performed validation assays by purifying the resting
CD4+ T cells from 16 patients in whom viremia was fully
suppressed by cART and by testing the reactivation poten-
tial of vorinostat in these ex vivo cultures. Following a 6 h
vorinostat exposure, HIV-1 RNA expression and chromatin
acetylation level were significantly up-regulated in 11 of the
16 patient cell cultures [230]. Of the 11 eligible/responder
patients, 8 patients agreed to receive a single 200 mg dose
of vorinostat, followed by a 400 mg dose at 4- to 5-weeks
later. In all 8 patients, this exposure resulted in a significant
increase in acetylation of total cellular histone H3, tempor-
ally associated with an increased (mean increase of 4.8 fold)
expression of unspliced HIV-1 gag RNA within resting
CD4+ T cells [230]. These results demonstrated that, at
least for a period of time in some infected cells, all of the
restrictions that limit the expression of latent proviral ge-
nomes have been overcome. In contrast, in this trial, the
authors observed neither an alteration of residual low-level
viremia nor a substantial reduction in the frequency of
replication-competent HIV-1 within resting CD4+ T cells
[230]. These latter results might reflect that multiple doses
of vorinostat, reactivation/anti-latency combination ap-
proach and/or additional interventions are required to clear
infected cells. Recently, a pilot clinical trial has started with
the HDACI panobinostat (called also LBH589) directed by
L. Østergaard (ClinicalTrials.gov NCT01680094) at Aarhus
University Hospital, Aarhus, Denmark. The primary out-
come measure is the change from baseline in HIV transcrip-
tion in latently infected CD4+ T-cells as quantified by copies
of unspliced HIV-RNA in the CD4+ T-cells of HIV-infected
patients on suppressive cART. These issues are important
goals for future studies as well as the development of
HDACI with improved specificity, potency and safety pro-
files for the selective targeting of latent proviral genomes.
Romidepsin (called also FK288), another HDACI ap-
proved by the FDA for the treatment of cutaneous T celllymphoma, has been shown to be one thousand fold
more potent then SAHA at inducing latent HIV-1, one
thousand to twenty thousand fold more potent in
inhibiting HDAC enzymatic activity and induced HIV
RNA expression ex vivo in 12 of 13 HIV + cART-treated
patients (Geleziunas et al., 2012, abstract Retrovirology,
9 (Suppl1):O2). The average increase in viral RNA was
approximately 8.6-fold (Geleziunas et al., 2012, abstract
Retrovirology, 9 (Suppl1):O2). Therefore, the HDACI
Romidepsin may be a very promising latent HIV-1 in-
ducer in vivo and its favorable toxicity profiles could
allow multiple-dose treatment. A clinical trial is on-
going with Romidepsin and the results are awaited with
high interest. Of note, it would be very important to
measure the size of the reservoirs during the course of
Romidepsin administration in the HIV-1+ patients en-
rolled in this trial.
PKC inducers also present several advantages in the
context of anti-HIV-1 purging strategies (described in sec-
tion 6.2). In this context, bryostatin, the only clinically
available PKC agonist [241] is currently tested with HIV-
1-infected patients in a pilot clinical trial directed by S.
Moreno, Department of Infectious Diseases, Ramon y
Cajal Hospital, Madrid, Spain (Table 1). This ongoing trial
evaluates the latent cell reservoir size, residual viremia and
cell associated viral RNA after a single dose of bryostatin-
1 and results are yet unavailable (Moreno S, 2012, abstract
Retrovirology, 9(Suppl 1):I16).
Disulfiram (DSF), a safe and well tolerated FDA-
approved drug to treat chronic alcoholism (described in
section 6.2), is currently evaluated in a pilot clinical trial
(ClinicalTrials.gov NCT01286259) under the direction of
S. Deeks at the University of California, San Francisco,
USA to assess whether a decrease in the frequency of rest-
ing CD4+ T cells harboring replication-competent HIV-1
occurs. This pilot clinical trial involved 14 patients on
cART with plasma viral loads below 50 copies HIV-1
RNA/ml of plasma. DSF was administrated for two weeks
and the frequency of latently infected cells as well as re-
sidual viral viremia was measured during disulfiram ad-
ministration. Preliminary results from this trial revealed
that disufiram administration resulted in a small transient
increase in viral load in some trial participants (Spivak
et al., 2012, Abstract 19th Conference on Retrovirus and
Opportunistic Infections. Seattle, March 5–8). No signifi-
cant change in the size of the latent reservoir was ob-
served at these intervals.
The hypothesis was that pharmacological reactivation
of latent HIV-1 would cause death of the infected cells
by viral cytophatic effects or host cytolytic T lympho-
cytes (CTLs), thereby decreasing the size of the latent
pool. Indeed, an overarching question is whether the in-
creases in viral RNA induced either by these compounds
will be sufficient to raise the amount of viral protein
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cytopathicity and/or elimination by cytotoxic T cells. In
this regard, the group of Siliciano has recently reported
that virus reactivation with vorinostat occurs in latently
infected primary CD4+ T cells generated in vitro, but is
not associated with death induced directly by viral protein,
i.e. viral cytopathic effect [416]. Moreover, unstimulated
HIV-specific CTL from cART-treated patients also fail to
kill autologous latently infected CD4+ T cells after latent
viruses are reactivated [416]. In contrast, antigen-specific
stimulation of patient CTLs prior to virus reactivation
leads to rapid killing of latently infected vorinostat-
reactivated cells [416]. Moreover, monocytes-macrophages
and myeloid dendritic cells are more resistant to the
cytophatic effects of the virus. Indeed, macrophages have
the peculiar capacity to accumulate virions in intracellular
vacuolar compartments, as observed originally in vivo in
macrophages infiltrating the brain of individuals with HIV-
1 encephalopathy and AIDS-associated dementia [417].
However, macrophages could be cleared by host mecha-
nisms if cytolytic T lymphocyte responses are boosted with
HIV-1 specific antigens to more efficiently kill infected
cells, in which latency has been reversed. Therefore, signifi-
cant boosting of CTL responses, through therapeutic vac-
cination or other means, prior to virus reactivation might
be an effective strategy for purging the latent pool and
thereby eradicating HIV-1 infection. Several approaches of
immunotherapy are reviewed in [389].
Conclusions
Overall, cumulated data indicate that a series of comple-
mentary mechanisms are involved in mediating HIV-1 la-
tency and reactivation. Different forms of latency probably
coexist in a single patient and vary from one patient to the
other. Therefore, further research in the basic mechanisms
of HIV-1 latency remains a priority because pharmaco-
logical anti-latency compounds would have to be multi-
pronged. Indeed, additional mechanistic studies of HIV-1
latency will identify novel targets for pharmacological ap-
proaches to reactivate latent reservoirs. Studying the
epigenome and DNA methylome of the host genes follow-
ing HIV-1 infection also constitutes an important issue.
Such combinatory strategies to eliminate HIV-1 reservoirs
with selective activators of viral expression, even if they do
not achieve total eradication, could lead to a decline of
HIV-1 reservoir levels sufficient to allow an efficient con-
trol of the infection by the host immune system. Lower
viral loads should permit highly welcome therapeutic in-
terruptions (“drug-free windows”). However, intentional
re-ignition of HIV-1 expression by the above approaches
aimed at eliminating latently infected cells has yet to be
further characterized in vivo. The future goals in HIV-1
research are varied but inter-connected. Improvement of
assays, technologies and in vitro (cellular) models forexploring potential reactivation strategies will be neces-
sary. Moreover, further studies on animal models aimed at
demonstrating their validity for HIV persistence should be
conducted. A better characterization of latent HIV infec-
tion in non-T cell HIV reservoirs, including tissue macro-
phages, astrocytes and dendritic cells is also waited. An
important effort remains to be done for the improvement
of the anti-latency drugs. In a therapeutic goal, the ideal
compounds should be orally available, active but not toxic
in a wide variety of cell types (or presenting mild host tox-
icities if administrated for limited periods of time), unable
to induce global immune activation and compatible with
the different components of cART. Careful consideration
of both short- and long-term toxicities, as well as activity
of these compounds and quantification of their effects on
viral reservoirs (including sanctuaries such as CNS and
GALT) are key issues in further developing such anti-
latency drugs. In addition to latency, the failure to cure
HIV-1 infection is believed to be the result of T-cell dys-
function stemming from persistent immune activation.
Therefore, new therapeutic strategies should also include
reversal of immune exhaustion and boosting of specific
anti-HIV-1 CTL immune responses.
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